| |
Sincerely, | | | Sincerely, |
| | ||
Ronald W. Hovsepian | | | Ajei S. Gopal |
Chairman of the Board | | | President and Chief Executive Officer |
| |
Sincerely, | | | Sincerely, |
| | ||
Ronald W. Hovsepian | | | Ajei S. Gopal |
Chairman of the Board | | | President and Chief Executive Officer |
1. | to adopt the merger agreement, which proposal is referred to as the “merger agreement proposal”; |
2. | to approve, on a non-binding, advisory basis, the merger-related compensation that will or may be paid to Ansys’ named executive officers in connection with the transactions contemplated by the merger agreement, which proposal is referred to as the “compensation proposal”; and |
3. | to approve the adjournment of the special meeting to solicit additional proxies if there are not sufficient votes at the time of the special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Ansys stockholders, which proposal is referred to as the “adjournment proposal.” |
• | the registration statement of which this proxy statement/prospectus is a part becoming effective in accordance with the provisions of the Securities Act of 1933, as amended, no stop order suspending its effectiveness being issued by the United States Securities and Exchange Commission, which is referred to as the “SEC,” and remaining in effect and there being no proceedings for that purpose having been initiated or threatened in writing by the SEC that have not been withdrawn; |
• | the shares of Synopsys common stock to be issued in the merger being approved for listing (subject to official notice of issuance) on the NASDAQ; |
• | the merger agreement being duly adopted at the special meeting by the required Ansys stockholder vote (as defined in the proxy statement/prospectus); |
• | expiration or termination of the waiting period (and any extension thereof) applicable to the completion of the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any period of time (and any extension thereof) agreed to with a governmental body in the United States not to complete the merger having expired or having been terminated; |
• | the expiration or termination of any waiting period (and any extension thereof) applicable to the completion of the merger under applicable foreign antitrust law or regulation of the specified jurisdictions (as defined in the proxy statement/prospectus), and the expiration or termination of any period of time (and any extension thereof) agreed to with a governmental body in any specified jurisdiction not to complete the merger; |
• | any governmental authorization or other consent required under applicable foreign antitrust law or regulation or foreign investment law in connection with the merger in each specified jurisdiction being obtained and being in full force and effect; and |
• | no temporary restraining order, preliminary or permanent injunction or other order preventing the completion of the merger having been issued by any governmental body in any of the specified jurisdictions and remains in effect, and there having not been any legal requirement enacted or deemed applicable to the merger by any governmental body in any specified jurisdiction that makes completion of the merger illegal. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any offer or proposal (other than an offer or proposal made or submitted by Synopsys) contemplating or otherwise relating to any acquisition transaction (as defined in the proxy statement/prospectus), which is referred to as an “acquisition proposal,” or any inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Synopsys) that would reasonably be expected to lead to an acquisition proposal, which is referred to as an “acquisition inquiry” (including by approving any transaction, or approving any person or entity (other than Synopsys and its affiliates) becoming an “interested stockholder” for purposes of Section 203 of the General Corporation Law of the State of Delaware) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person or entity in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person or entity with respect to any acquisition proposal or acquisition inquiry (other than to inform such person or entity of the non-solicitation covenants in the merger agreement); |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement, as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101); or |
• | resolve or publicly propose to take any of the foregoing actions. |
• | withdraw or modify in a manner adverse to Synopsys, or permit the withdrawal or the modification in a manner adverse to Synopsys of, the Ansys board of directors’ unanimous: (i) determination that the merger agreement and the merger is advisable and fair to and in the best interests of Ansys and its stockholders and (ii) recommendation that Ansys stockholders vote to adopt the merger agreement by voting “FOR” the approval of the merger agreement proposal at the special meeting, which is referred to as the “Ansys board recommendation”; |
• | recommend the approval, acceptance or adoption of, or approve, endorse, accept or adopt, any acquisition proposal; |
• | approve or recommend, or cause or permit Ansys or any of its subsidiaries to execute or enter into, any letter of intent, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar document or contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve, agree or publicly propose, or permit Ansys or any of its subsidiaries, or any of its or their respective representatives, to agree or publicly propose, to take any of the actions contemplated in any of the preceding bullets. |
• | by the mutual written consent of Synopsys and Ansys; |
• | by either Synopsys and Ansys if the merger has not been completed by 11:59 p.m. (California time) on January 15, 2025, which may be extended to July 15, 2025 and further to January 15, 2026 in certain circumstances in accordance with the terms of the merger agreement, which is referred to as the “end date” (as it may be extended in accordance with the merger agreement) (however, a party is not permitted to terminate the merger agreement on such basis if the failure to complete the merger by the end date is primarily attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time in breach of such party’s obligations); |
• | by either Synopsys or Ansys if: (i) a governmental body in any specified jurisdiction has issued a final and nonappealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger; or (ii) there has been any applicable legal requirement enacted, enforced or deemed applicable to the merger by any governmental body in any specified jurisdiction that would make completion of the merger illegal; |
• | by either Synopsys or Ansys upon a no stockholder approval event (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117); |
• | by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event (as defined in the proxy statement/prospectus) has occurred; |
• | by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into an alternative acquisition agreement (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117), subject to compliance with certain obligations under the merger agreement; or |
• | by either Synopsys or Ansys if, subject to certain exceptions, (i) any of the other party’s representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement or became inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that the closing condition relating to the accuracy of such other party’s representations and warranties would not be satisfied; or (ii) any of the other party’s covenants or obligations contained in the merger agreement was breached such that the closing condition relating to the performance by such other party of its covenants would not be satisfied. |
For Information Regarding Synopsys: Synopsys, Inc. 675 Almanor Ave. Sunnyvale, California 94085 (650) 584-5000 Attention: Corporate Secretary | | | For Information Regarding Ansys: ANSYS, Inc. 2600 ANSYS Drive Canonsburg, Pennsylvania 15317 (844) 462-6797 Attention: Corporate Secretary |
• | “acquisition inquiry” refers to an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Synopsys) that would reasonably be expected to lead to an acquisition proposal; |
• | “acquisition proposal” refers to any offer or proposal (other than an offer or proposal made or submitted by Synopsys) contemplating or otherwise relating to any acquisition transaction; |
• | “acquisition transaction” refers to any transaction or series of related transactions (other than the transactions contemplated by the merger agreement) involving: |
○ | any merger, consolidation, amalgamation, plan or scheme of arrangement, share exchange, business combination, joint venture, reorganization, recapitalization, tender offer, exchange offer or other similar transaction involving Ansys, except for any such transaction in which the Ansys stockholders immediately preceding such transaction continue to hold immediately following such transaction, directly or indirectly, 85% or more of the equity interests in the surviving or resulting entity in such transaction (whether by voting power or number of shares); |
○ | any issuance of securities, acquisition of securities or other transaction: (a) in which a person, entity or “group” (as defined in the Exchange Act and the rules promulgated thereunder) of persons or entities directly or indirectly acquires beneficial or record ownership of securities representing 15% or more of the outstanding securities of any class (or instruments convertible into or exercisable or exchangeable for 15% or more of any such class) of Ansys; or (b) in which Ansys issues securities representing 15% or more of the outstanding securities of any class (or instruments convertible into or exercisable or exchangeable for 15% or more of any such class) of Ansys; or |
○ | any sale, lease, exchange, transfer, license, sublicense or disposition by Ansys or any of its subsidiaries to any person, entity or “group” (as defined in the Exchange Act and the rules |
• | “adjournment proposal” refers to the proposal for Ansys stockholders to approve the adjournment of the Ansys special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Ansys special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Ansys stockholders; |
• | “Ansys” means ANSYS, Inc., a Delaware corporation |
• | “Ansys board of directors” refers to the board of directors of Ansys; |
• | “Ansys board recommendation” refers to the Ansys board of directors’ unanimous: (i) determination that the merger agreement and the merger is advisable and fair to and in the best interests of Ansys and its stockholders and (ii) recommendation that Ansys stockholders vote to adopt the merger agreement by voting “FOR” the approval of the merger agreement proposal at the special meeting; |
• | “Ansys bylaws” refers to the Fifth Amended and Restated By-Laws of Ansys; |
• | “Ansys charter” refers to the Restated Certificate of Incorporation of Ansys; |
• | “Ansys common stock” refers to the common stock, $0.01 par value per share, of Ansys; |
• | “Ansys credit agreement” refers to that certain credit agreement, dated as of June 30, 2022 (as amended by Amendment No. 1 to Credit Agreement, dated as of September 29, 2023), among Ansys, as Borrower, the Designated Borrowers from time to time party thereto, each Lender from time to time party thereto, PNC Bank, National Association, as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other L/C Issuers from time to time party thereto; |
• | “Ansys excluded shares” refers to, collectively, (i) shares of Ansys common stock owned by Ansys (or in Ansys’ treasury), Synopsys or any of their respective wholly-owned subsidiaries immediately prior to the effective time and (ii) shares of Ansys common stock held by a holder who has made a proper demand for appraisal of such shares in accordance with Section 262 of the DGCL and not validly withdrawn such demand or otherwise lost their rights of appraisal with respect to such shares pursuant to Section 262 of the DGCL; |
• | “Ansys equity plans” refers to, collectively, the 2021 Equity and Incentive Compensation Plan, the Fourth Amended and Restated 1996 Stock Option and Grant Plan and the Fifth Amended and Restated 1996 Stock Option and Grant Plan; |
• | “Ansys PSUs” refers to Ansys RSUs that vest on the basis of time and the achievement of performance targets and pursuant to which the holder has a right to receive shares of Ansys common stock or cash following the vesting or lapse of restrictions applicable to such performance stock unit; |
• | “Ansys RSUs” refers to Ansys restricted stock units; |
• | “Ansys stockholders” refers to holders of Ansys common stock; |
• | “assumed shares” refers to shares of Synopsys common stock resulting from the conversion of residual shares remaining available for issuance under the Ansys equity plans at the effective time; |
• | “capital markets issuance” refers to any of the following, the use of proceeds of which are for the satisfaction of all of Synopsys’ payment obligations under the merger agreement due at the closing: one or more issuances of non-convertible and non-exchangeable debt securities in an offering, which may consist of multiple tranches, registered under the Securities Act or in a private placement pursuant to an exemption from the registration requirements of the Securities Act; |
• | “closing” refers to the completion of the merger and the other contemplated transactions; |
• | “closing date” refers to the date on which the closing occurs; |
• | “Code” refers to the Internal Revenue Code of 1986, as amended; |
• | “combined company” refers to Synopsys immediately following the completion of the merger and the other transactions contemplated by the merger agreement; |
• | “commitment parties” refers, collectively, to Bank of America, N.A., BofA Securities, Inc., HSBC Securities (USA) Inc., HSBC Bank USA, National Association, The Hongkong and Shanghai Banking Corporation Limited and JPMorgan Chase Bank, N.A.; |
• | “compensation proposal” refers to the proposal for Ansys stockholders to approve on a non-binding advisory basis, the merger-related executive officer compensation payments that will or may be paid by Ansys to its named executive officers in connection with the merger; |
• | “confidentiality agreement” refers to the confidentiality agreement by and between Ansys and Synopsys with respect to the transaction; |
• | “conversion ratio” refers to an amount equal to the sum of the exchange ratio plus the quotient (rounded down to four decimal places) obtained by dividing the per share cash amount by the Synopsys measurement price; |
• | “converted options” refers to each Ansys option (other than (i) a specified option or (ii) an out-of-the-money option held by a person or entity who, as of immediately prior to the effective time, is no longer an employee or other service provider to Ansys or any of its subsidiaries) that is assumed by Synopsys and converted into an option to purchase on the same terms and conditions as were applicable under such Ansys option, a certain number of shares of Synopsys common stock; |
• | “converted RSUs” refers to Ansys RSUs outstanding and unvested immediately prior to the effective time and that are not specified RSUs; |
• | “Court of Chancery” refers to the Court of Chancery of the State of Delaware; |
• | “debt commitment letter” refers to the commitment letter, dated as of January 15, 2024, by and among Synopsys and the commitment parties, as it may be amended from time to time; |
• | “DGCL” refers to the General Corporation Law of the State of Delaware; |
• | “DOJ” refers to the U.S. Department of Justice; |
• | “effective time” refers to the date and time when the merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the merger is filed with the Secretary of State of the State of Delaware, or such later date and time as maybe mutually agreed to by Synopsys and Ansys and specified in the certificate of merger; |
• | “end date” refers to January 15, 2025, which may be extended to July 15, 2025 and further to January 15, 2026 in certain circumstances in accordance with the terms of the merger agreement; |
• | “equity award cash consideration amount” refers to an amount in cash equal to the sum of the per share cash amount plus the product of (i) the exchange ratio multiplied by (ii) the Synopsys measurement price; |
• | “ESPP” refers to the Ansys 2022 Employee Stock Purchase Plan, as amended; |
• | “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; |
• | “exchange ratio” refers to 0.3450, which reflects the number of shares of Synopsys common stock that Ansys stockholders will be entitled to receive in the merger for each issued and outstanding share of Ansys common stock held immediately prior to the effective time pursuant to, and in accordance with, the terms of the merger agreement; |
• | “exchange ratio reduction amount” refers to the minimum amount of reduction in the exchange ratio necessary (rounded down to four decimal places) such that the aggregate number of shares of Synopsys |
• | “FTC” refers to the U.S. Federal Trade Commission; |
• | “GAAP” refers to U.S. generally accepted accounting principles; |
• | “HSR Act” refers to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; |
• | “in-the-money option” means an option to purchase shares of Ansys common stock that is unexpired, unexercised and outstanding immediately prior to the effective time and has a per share exercise price for the Ansys common stock subject to such option that is less than the equity award cash consideration amount; |
• | “maximum share number” refers to 19.9999% of the issued and outstanding shares of Synopsys common stock immediately prior to the effective time; |
• | “merger” refers to the merger of Merger Sub with and into Ansys; |
• | “merger agreement” refers to that certain Agreement and Plan of Merger, dated as of January 15, 2024, by and among Synopsys, Merger Sub and Ansys, as it may be amended from time to time; |
• | “merger agreement proposal” refers to the proposal for the Ansys stockholders to adopt the merger agreement; |
• | “merger consideration” refers to (i) 0.3450 of a share of Synopsys common stock and $197.00 in cash, without interest; (ii) any cash in lieu of fractional shares of shares of Synopsys common stock that a holder of Ansys common stock is entitled to receive pursuant to the merger agreement; and (iii) any dividends or other distributions that a holder of Ansys common stock is entitled to receive with respect to a share of Ansys common stock pursuant to the merger agreement, collectively, which each share of Ansys common stock that is outstanding immediately prior to the effective time (other than Ansys excluded shares) will be converted into the right to receive pursuant to, and in accordance with, the terms of the merger agreement; |
• | “Merger Sub” refers to ALTA Acquisition Corp.; |
• | “NASDAQ” refers to the Nasdaq Global Select Market; |
• | “out-of-the-money option” refers to an option to purchase shares of Ansys common stock that is unexpired, unexercised and outstanding immediately prior to the effective time and which has a per share exercise price for the Ansys common stock subject to such option that is equal to or greater than the equity award cash consideration amount; |
• | “per share cash amount” refers to $197.00 in cash, without interest; |
• | “pre-closing period” refers to the period from the date of the merger agreement and the earlier to occur of (i) the effective time and (ii) the valid termination of the merger agreement pursuant to its terms; |
• | “required Ansys stockholder vote” refers to the affirmative vote of the holders of a majority of the shares of Ansys common stock outstanding on the record date for the special meeting; |
• | “revolving credit facility” refers to the amended and restated credit agreement, dated as of February 13, 2024, as it may be further amended, by and among Synopsys, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent; |
• | “second request” refers to a Request for Additional Information and Documentary Material issued by the Antitrust Division of the DOJ or the FTC; |
• | “Securities Act” refers to the Securities Act of 1933, as amended; |
• | “specified option” refers to each in-the-money option that is vested or unvested that is held by a person who, as of immediately prior to the effective time, is no longer an employee or other service provider of Ansys or its subsidiaries; |
• | “specified RSU” refers to each Ansys RSU that (i) is vested but not yet settled as of immediately prior to the effective time, (ii) is outstanding as of immediately prior to the effective time and was granted to a non-employee member of Ansys’ board of directors, (iii) vests effective as of the effective time in accordance with its terms, or (iv) is outstanding and not forfeited in accordance with its terms immediately prior to the effective time and held by a person who, as of immediately prior to the effective time, is no longer an employee or other service provider to Ansys or its subsidiaries; |
• | “superior offer” refers to a bona fide, written acquisition proposal submitted to Ansys after the date of the merger agreement that is on terms and conditions that the Ansys board of directors determines in good faith, after having taken into account the advice of an independent financial advisor of nationally recognized reputation and Ansys’ outside legal counsel and the likelihood and timing of completion of the acquisition transaction contemplated by such acquisition proposal, to be more favorable to Ansys’ stockholders than the merger. For purposes of the reference to an “acquisition proposal” in this definition, all references to “15%” and “85%” in the definition of “acquisition transaction” will be deemed to refer to “50%”; |
• | “surviving corporation” refers to Ansys, following completion of the merger, as a wholly owned subsidiary of Synopsys; |
• | “Synopsys” refers to Synopsys, Inc., a Delaware corporation; |
• | “Synopsys board of directors” refers to the board of directors of Synopsys; |
• | “Synopsys bylaws” refers to the Amended and Restated Bylaws of Synopsys; |
• | “Synopsys charter” refers to the Restated Certificate of Incorporation of Synopsys; |
• | “Synopsys common stock” refers to the common stock, $0.01 par value per share, of Synopsys; |
• | “Synopsys measurement price” refers to the volume weighted average trading price of Synopsys common stock for the five consecutive trading days ending on the trading day immediately prior to the date on which the effective time occurs; |
• | “Synopsys RSUs” refers to Synopsys restricted stock units; |
• | “term loan credit agreement” refers to the term loan facility credit agreement, dated as of February 13, 2024, by and among Synopsys, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto; and |
• | A “triggering event” is deemed to have occurred if (i) the Ansys board of directors or any committee thereof has: (a) withdrawn the Ansys board recommendation; (b) modified the Ansys board recommendation in a manner adverse to Synopsys; or (c) taken, authorized or publicly proposed any of the prohibited board actions (as defined in “The Merger Agreement—Ansys Stockholder Meeting; Ansys Board Recommendation” beginning on page 103); (ii) Ansys has failed to include the Ansys board recommendation in this proxy statement/prospectus; (iii) Synopsys has requested, after an acquisition proposal has been publicly disclosed, commenced, announced or made, that the Ansys board recommendation be reaffirmed publicly, and the Ansys board of directors has failed to reaffirm, unanimously and publicly, the Ansys board recommendation within 10 business days after such request was made (or, if earlier, prior to the special meeting); (iv) a tender or exchange offer relating to shares Ansys common stock has commenced and Ansys has not sent to its securityholders, within 10 business days after the commencement of such tender or exchange offer, if such offer has not been withdrawn prior to the end of such 10 business day period (or, if earlier, prior to the special meeting), a statement disclosing that Ansys recommends rejection of such tender or exchange offer and reaffirming the board recommendation; (v) Ansys has called or convened a meeting of the Ansys stockholders to consider an acquisition proposal or has failed to convene or hold the special meeting in accordance with certain provisions of the merger agreement; or (vi) Ansys or any of its subsidiaries or any representative of Ansys or any of its subsidiaries has breached (or be deemed to have breached) any of the no-shop covenants (as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101) or the board recommendation covenants (as defined in “The Merger Agreement—Ansys Stockholder Meeting; Ansys Board Recommendation” beginning on page 103) in any material respect. |
Q: | Why am I receiving this proxy statement/prospectus? |
A: | You are receiving this proxy statement/prospectus because Synopsys has agreed to acquire Ansys through a merger of Merger Sub with and into Ansys, with Ansys surviving the merger as a wholly owned subsidiary of Synopsys. The merger agreement governs the terms of the merger and is attached to this proxy statement/prospectus as Annex A. |
Q: | When and where will the special meeting take place? |
A: | The special meeting will be held virtually via the special meeting website, on May 22, 2024, at 11:00 a.m., Eastern Time. |
Q: | Does my vote matter? |
A: | Yes, your vote is very important, regardless of the number of shares that you own. The merger cannot be completed unless the merger agreement is adopted by Ansys stockholders. |
Q: | What will I receive if the merger is completed? |
A: | If the merger is completed, each share of Ansys common stock outstanding as of immediately prior to the effective time (other than Ansys excluded shares) will be converted into the right to receive (a) $197.00 in cash, without interest, and (b) 0.3450 of a share of Synopsys common stock. No fractional shares of Synopsys common stock will be issued upon the conversion of shares of Ansys common stock pursuant to the merger agreement. Each holder of shares of Ansys common stock who would otherwise have been |
Q: | Will Ansys equity awards be affected by the merger? |
A: | Ansys Options |
Q: | What will happen to the Ansys 2022 Employee Stock Purchase Plan? |
A: | For the ESPP, Ansys will take action to provide that: (i) no new offering period (or similar period during which shares may be purchased) will commence under the ESPP following the date of the merger agreement; (ii) participants in the ESPP may not increase their payroll deductions from those in effect on the date of the merger agreement; and (iii) no new participants may commence participation in the ESPP following the date of the merger agreement. In addition, prior to the effective time, Ansys will take all actions necessary to: (a) cause any offering period (or similar period during which shares may be purchased) in progress as of the date of the merger agreement to be the final offering period under the ESPP and to be terminated no later than five business days prior to the date on which the effective time occurs; (b) make any pro-rata adjustments that may be necessary to reflect the shortened offering period (or similar period), but otherwise treat such shortened offering period (or similar period) as a fully effective and completed offering period for all purposes under the ESPP; (c) cause each participant’s then-outstanding share purchase right under the ESPP to be exercised as of no later than two business days prior to the date on which the effective time occurs (referred to herein as the “final exercise date”); and (d) terminate the ESPP as of, and subject to the occurrence of, the effective time. On the final exercise date, funds credited as of such date under the ESPP within the associated accumulated payroll withholding account for each participant under the ESPP will be used to purchase shares of Ansys common stock in accordance with the terms of the ESPP (as amended pursuant to the foregoing), and each share purchased immediately prior to the effective time will be canceled at the effective time and converted into the right to receive the merger consideration in accordance with the terms of the merger agreement, subject to withholding of any applicable income and employment withholding taxes. Any accumulated contributions of each participant under the ESPP as of immediately prior to the effective time will, to the extent not used to purchase shares under the ESPP, be refunded to such participant as promptly as practicable following the final exercise date (without interest). |
Q: | How does the Ansys board of directors recommend that I vote at the special meeting? |
A: | The Ansys board of directors unanimously recommends that you vote “FOR” the merger agreement proposal, “FOR” the compensation proposal and “FOR” the adjournment proposal. |
Q: | Who is entitled to vote at the special meeting? |
A: | The record date for the special meeting is April 9, 2024, which is referred to as the “record date.” All holders of shares of Ansys common stock who held shares at the close of business on the record date are entitled to receive notice of, and to vote at, the special meeting. Each such holder of Ansys common stock is entitled to cast one vote on each matter properly brought before the special meeting for each share of Ansys common stock that such holder owned of record as of the record date. Attendance at the special meeting via the special meeting website is not required to vote. See below and the section entitled “The Special Meeting—Methods of Voting” beginning on page 45 for instructions on how to vote your shares without attending the special meeting. |
Q: | What is a proxy? |
A: | A stockholder’s legal designation of another person to vote shares of such stockholder’s common stock at a special meeting is referred to as a proxy. The document used to designate a proxy to vote your shares of Ansys common stock is referred to as a proxy card. |
Q: | How many votes do I have for the special meeting? |
A: | Each Ansys stockholder is entitled to one vote for each share of Ansys common stock held of record as of the close of business on the record date. As of the close of business on the record date, there were 87,299,981 outstanding shares of Ansys common stock. |
Q: | What constitutes a quorum for the special meeting? |
A: | The holders of a majority of the shares of Ansys common stock entitled to vote at the special meeting must be present or represented at the special meeting by proxy in order to constitute a quorum. |
Q: | Will the Synopsys common stock that I receive in the merger be publicly traded? |
A: | Yes. The shares of Synopsys common stock to be issued in the merger will be listed for trading on the NASDAQ under the symbol “SNPS.” |
Q: | What happens if the merger is not completed? |
A: | If the merger agreement is not adopted by Ansys stockholders or if the merger is not completed for any other reason, Ansys stockholders will not receive any merger consideration for their shares of Ansys common stock in connection with the merger. Instead, Ansys will remain an independent public company and Ansys common stock will continue to be listed and traded on the NASDAQ. If the merger agreement is terminated under specified circumstances, either Ansys or Synopsys may be required to pay the other party a termination fee. See the section entitled “The Merger Agreement—Transaction Expenses and Termination Fees” beginning on page 119 for a more detailed discussion of the respective termination fees. |
Q: | Will the merger affect the board of directors of Synopsys after the merger? |
A: | Yes. At the effective time, two members of the Ansys board of directors selected by mutual agreement of Synopsys and Ansys will be appointed to the Synopsys board of directors. On March 19, 2024, Synopsys |
Q: | What is a “broker non-vote”? |
A: | Under the NASDAQ rules, banks, brokers and other nominees may use their discretion to vote “uninstructed” shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. All the proposals currently scheduled for consideration at the special meeting are “non-routine” matters. |
Q: | What stockholder vote is required for the approval of each proposal at the special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the special meeting? |
A: | Proposal 1: Merger agreement proposal. The adoption of the merger agreement by Ansys stockholders requires the affirmative vote of a majority of the outstanding shares of Ansys common stock entitled to vote thereon. Accordingly, an Ansys stockholder’s abstention from voting, a broker non-vote or the failure of an Ansys stockholder to vote (including the failure of an Ansys stockholder who holds shares in “street name” through a bank, broker or other nominee to give voting instructions to that bank, broker or other nominee) will have the same effect as a vote “AGAINST” the merger agreement proposal. |
Q: | Why am I being asked to consider and vote on a proposal to approve, by non-binding, advisory vote, merger-related compensation arrangements for Ansys’ named executive officers referred to as the compensation proposal? |
A: | Under the SEC rules, Ansys is required to seek a non-binding, advisory vote of its stockholders with respect to the compensation that may be paid or become payable to Ansys’ named executive officers that is based on or otherwise relates to the merger, also known as “golden parachute” compensation. |
Q: | What happens if Ansys stockholders do not approve, by non-binding, advisory vote, the compensation proposal? |
A: | The vote on the proposal to approve the merger-related compensation arrangements for Ansys’ named executive officers is separate and apart from the votes to approve the other proposals being presented at the special meeting. Because the vote on the proposal to approve the merger-related executive compensation is advisory in nature only, it will not be binding upon Synopsys or Ansys. Accordingly, the merger-related compensation will be paid to Ansys’ named executive officers to the extent payable in accordance with the terms of their compensation agreements and arrangements even if Ansys’ stockholders do not approve the proposal to approve the merger-related compensation. |
Q: | How can I vote my shares at the special meeting? |
A: | Record Holders. Shares held directly in your name as the holder of record of Ansys common stock may be voted at the special meeting. If you choose to vote your shares virtually at the special meeting via the special meeting website, please follow the instructions on your proxy card. |
Q: | How can I vote my shares without attending the special meeting? |
A: | Whether you hold your shares directly as the stockholder of record of Ansys or beneficially in “street name,” you may direct your vote by proxy without attending the special meeting via the special meeting website. You can vote by proxy over the Internet, or by telephone or by mail by following the instructions provided in the enclosed proxy card. Please note that if you hold shares beneficially in “street name,” you should follow the voting instructions provided by your bank, broker or other nominee. |
Q: | What is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in “street name?” |
A: | If your shares of common stock in Ansys are registered directly in your name with American Stock Transfer & Trust Company, Ansys’ transfer agent, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote, or to grant a proxy for your vote directly to Ansys or to a third party to vote, at the special meeting. |
Q: | If my shares of Ansys common stock are held in “street name” by my bank, broker or other nominee, will my bank, broker or other nominee automatically vote those shares for me? |
A: | No. Your bank, broker or other nominee will only be permitted to vote your shares of Ansys common stock if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided |
Q: | What should I do if I receive more than one set of voting materials for the same special meeting? |
A: | If you hold shares of Ansys common stock in “street name” and also directly in your name as a stockholder of record or otherwise, or if you hold shares of Ansys common stock in more than one brokerage account, you may receive more than one set of voting materials relating to the same special meeting. |
Q: | If a stockholder submits a proxy, how are the shares of Ansys common stock voted? |
A: | Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of Ansys common stock in the way that you indicate. When completing the Internet or telephone voting processes or the proxy card, you may specify whether your shares of Ansys common stock should be voted for or against, or abstain from voting on, all, some or none of the specific items of business to come before the special meeting. |
Q: | How will my shares of Ansys common stock be voted if I return a blank proxy? |
A: | If you sign, date and return your proxy card and do not indicate how you want your shares of Ansys common stock to be voted, then your shares of Ansys common stock will be voted in accordance with the recommendation of the Ansys’ board of directors and “FOR” the merger agreement proposal, “FOR” the compensation proposal and “FOR” the adjournment proposal. |
Q: | Can I change my vote after I have submitted my proxy? |
A: | Any stockholder submitting a proxy has the right to revoke it before the proxy is voted at the special meeting by doing any of the following: |
• | sending a signed written notice of revocation to Ansys’ corporate secretary; |
• | voting again by the Internet or telephone at a later time before the closing of the voting facilities at 11:59 p.m., Eastern Time, on the date before the special meeting; |
• | submitting a properly signed proxy card with a later date; or |
• | attending virtually and voting at the special meeting via the special meeting website. |
Q: | If I hold my shares in “street name,” can I change my voting instructions after I have submitted voting instructions to my bank, broker or other nominee? |
A: | If your shares are held in the name of a bank, broker or other nominee and you previously provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions. |
Q: | Where can I find the voting results of the special meeting? |
A: | The preliminary voting results for the special meeting will be announced at the special meeting. In addition, within four business days following certification of the final voting results, Ansys will file the final voting results of its special meeting with the SEC on a Current Report on Form 8-K. |
Q: | If I do not favor the merger, what are my rights? |
A: | If you are not in favor of the merger, you may vote your shares of Ansys common stock against the merger agreement proposal. Information about how Ansys stockholders may vote on the proposals being considered in connection with the merger can be found under the section entitled “The Special Meeting” beginning on page 43. |
Q: | Are there any risks that I should consider in deciding whether to vote for the approval of the merger agreement proposal? |
A: | Yes. You should read and carefully consider the risk factors set forth in the section entitled “Risk Factors” beginning on page 27. You also should read and carefully consider the risk factors of Synopsys and Ansys contained in the documents that are incorporated by reference into this proxy statement/prospectus. |
Q: | What happens if I sell my shares of Ansys common stock after the record date but before the special meeting? |
A: | The record date is earlier than the date of the special meeting. If you transfer your shares of Ansys common stock after the record date but before the special meeting, you will, unless special arrangements are made, retain your right to vote at the special meeting. |
Q: | Should I send in my stock certificates now? |
A: | No. Please do not send in your stock certificates with your proxy. After the merger is completed, an exchange agent designated by Synopsys (which will be Synopsys’ transfer agent or another bank or trust company reasonably acceptable to Ansys), which is referred to as the exchange agent, will send you instructions for exchanging Ansys stock certificates for the consideration to be received in the merger. See the section entitled “The Merger Agreement—Exchange Procedures” beginning on page 93. |
Q: | Who will solicit and pay the cost of soliciting proxies? |
A: | Ansys has engaged Mackenzie Partners, Inc., which is referred to as Mackenzie, to assist in the solicitation of proxies for the special meeting. Ansys estimates that it will pay Mackenzie a fee of approximately $75,000, plus reimbursement for certain fees and expenses. Ansys has agreed to indemnify Mackenzie against various liabilities and expenses that relate to or arise out of its solicitation of proxies (subject to certain exceptions). Ansys also may be required to reimburse banks, brokers and other custodians, nominees |
Q: | What are the United States federal income tax consequences of the merger to U.S. holders of Ansys common stock? |
A: | The receipt of the merger consideration in exchange for shares of Ansys common stock pursuant to the merger will be a taxable transaction for U.S. federal income tax purposes. Accordingly, U.S. holders (as defined below in the section entitled “U.S. Federal Income Tax Consequences of the Merger,” beginning on page 147) generally will recognize gain or loss equal to the difference between (i) the sum of the cash and the fair market value (as of the effective time) of the stock consideration they receive in the merger and (ii) their adjusted tax basis in Ansys common stock surrendered in exchange therefor. See the section entitled “U.S. Federal Income Tax Consequences of the Merger” for more information. You should be aware that the tax consequences to you of the merger may depend upon your own situation. In addition, you may be subject to U.S. federal, state, local and non-U.S. tax laws that are not discussed in this proxy statement/prospectus. You should therefore consult with your own tax advisor(s) for a full understanding of the tax consequences to you of the merger. |
Q: | When is the merger expected to be completed? |
A: | Subject to the satisfaction or waiver of the closing conditions described under the section entitled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114, including the adoption of the merger agreement by Ansys stockholders, the merger is expected to be completed in the first half of 2025. However, neither Ansys nor Synopsys can predict the actual date on which the merger will be completed, or if the merger will be completed at all, because completion of the merger is subject to conditions and factors outside the control of both companies. Synopsys and Ansys hope to complete the merger as soon as reasonably practicable. See also the section entitled “The Merger—Regulatory Approvals and Related Matters” beginning on page 85. |
Q: | What are the conditions to completion of the merger? |
A: | The merger is subject to a number of conditions to closing as specified in the merger agreement. These closing conditions include, among others, (i) the adoption of the merger agreement by the holders of a majority of the outstanding shares of Ansys common stock, (ii) the expiration or early termination of the applicable waiting period under the HSR Act and the approval of the merger under certain other antitrust and foreign investment regimes, (iii) the absence of any order, injunction, ruling issued by any governmental body in the United States or certain other jurisdictions preventing the completion of the merger that remains in effect, or legal requirement enacted or deemed applicable by a governmental body in certain jurisdictions making the completion of the merger illegal, (iv) the effectiveness of the registration statement of Synopsys pursuant to which shares of Synopsys common stock to be issued in the merger will be registered with the SEC and the absence of any stop order or proceedings by the SEC with respect thereto, (v) the shares of Synopsys common stock to be issued in the merger being approved for listing on the NASDAQ, (vi) the accuracy of certain representations and warranties of the other party and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the merger agreement and (vii) the absence of a material adverse effect with respect to Synopsys or Ansys after the date of the merger agreement that is continuing. No assurance can be given that the required stockholder, governmental and regulatory consents and approvals will be obtained or that the required conditions to closing will be satisfied, and, even if all required consents and approvals are obtained and the conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the merger could cause Synopsys not to realize, or to be delayed in realizing, some or all the benefits that Synopsys and Ansys expect to achieve if the merger is successfully completed within its expected time frame. For a more complete summary of the conditions that must be satisfied or waived before completion of the merger, see the section entitled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114. |
Q: | What equity stakes will Ansys stockholders hold in Synopsys immediately following the merger? |
A: | Upon completion of the merger, Ansys stockholders are expected to hold approximately 16.5% of the issued and outstanding shares of the combined company immediately following the completion of the merger. The exact equity stake of Ansys stockholders in the combined company immediately following the merger will depend on the number of shares of Synopsys common stock and Ansys common stock issued and outstanding immediately before the merger. |
Q: | If I am an Ansys stockholder and I have not demanded my appraisal rights, how will I receive the merger consideration to which I am entitled? |
A: | If you hold your shares of Ansys common stock through The Depository Trust Company, which is referred to as DTC, in book-entry form and you have not demanded your appraisal rights (more information on appraisal rights may be found in the section entitled “Appraisal Rights” beginning on page 157), you will not be required to take any specific actions to exchange your shares for the merger consideration. After the completion of the merger, shares of Ansys common stock held through DTC in book-entry form will be automatically exchanged for the cash consideration and for shares of Synopsys common stock in book-entry form and cash to be paid in lieu of any fractional share of Synopsys common stock to which you are entitled. If you hold your shares of Ansys common stock in certificated form, or in book-entry form but not through DTC, after receiving the proper documentation from you, following the effective time, the exchange agent will deliver to you the cash consideration, the Synopsys common stock (in book-entry form) and cash in lieu of fractional shares to which you are entitled. More information may be found in the sections entitled “The Merger—Exchange of Shares and Payment Procedures” beginning on page 87 and “The Merger Agreement—Exchange Procedures” beginning on page 93. |
Q: | What should I do now? |
A: | You should read this proxy statement/prospectus carefully and in its entirety, including the annexes, and return your completed, signed and dated proxy card by mail in the enclosed postage-paid envelope or submit your voting instructions by telephone or over the Internet as soon as possible so that your shares will be voted in accordance with your instructions. |
Q: | Whom do I call if I have questions about the special meeting or the merger? |
A: | If you have questions about the special meeting or the merger, or desire additional copies of this proxy statement/prospectus or additional proxies, you may contact Ansys’ proxy solicitor: |
• | at the effective time, each Ansys equity award held by a director or executive officer will receive the treatment described in the section entitled “The Merger Agreement—Treatment of Ansys Equity Awards”; |
• | eligibility of Ansys’ executive officers to receive severance payments and benefits (including equity award vesting acceleration) either under their employment agreement with Ansys or under an Ansys executive severance plan or award agreement, as described in more detail in the section of this proxy statement captioned “The Merger—Interests of Ansys’ Directors and Executive Officers in the Merger—Potential Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time”; |
• | receipt by each non-employee member of the Ansys board of directors of a one-time cash payment of $35,000 and a monthly cash payment in the amount of $15,000 for the period commencing in September 2023 and through and including the earlier to occur of the month in which the effective time occurs and the month in which the merger agreement is terminated in accordance with its terms, as described in more detail in the section of this proxy statement captioned “The Merger—Interests of Ansys’ Directors and Executive Officers in the Merger—Non-Employee Director Compensation”; |
• | appointment to the Synopsys board of directors of two members of the Ansys board of directors who are mutually agreed between Ansys and Synopsys; and |
• | continued indemnification and directors’ and officers’ liability insurance to be provided by the surviving corporation. |
• | the registration statement of which this proxy statement/prospectus is a part becoming effective in accordance with the provisions of the Securities Act, no stop order suspending its effectiveness being issued by the SEC and remaining in effect and there being no proceedings for that purpose having been initiated or threatened in writing by the SEC that have not been withdrawn; |
• | the shares of Synopsys common stock to be issued in the merger being approved for listing (subject to official notice of issuance) on the NASDAQ; |
• | the merger agreement being duly adopted at the special meeting by the required Ansys stockholder vote; |
• | the expiration or termination of the waiting period (and any extension thereof) applicable to the completion of the merger under the HSR Act, and any period of time (and any extension thereof) agreed to with a governmental body in the United States not to complete the merger having expired or having been terminated; |
• | the expiration or termination of any waiting period (and any extension thereof) applicable to the completion of the merger under applicable foreign antitrust law or regulation of the specified jurisdictions, and the expiration or termination of any period of time (and any extension thereof) agreed to with a governmental body in any specified jurisdiction not to complete the merger; |
• | any governmental authorization or other consent required under applicable foreign antitrust law or regulation or foreign investment law in connection with the merger in each specified jurisdiction being obtained and being in full force and effect; and |
• | no temporary restraining order, preliminary or permanent injunction or other order preventing the completion of the merger having been issued by any governmental body in any of the specified jurisdictions and remains in effect, and there having not been any legal requirement enacted or deemed applicable to the merger by any governmental body in any specified jurisdiction that makes completion of the merger illegal. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry (including by approving any transaction, or approving any person or entity (other than Synopsys and its affiliates) becoming an “interested stockholder” for purposes of Section 203 of the DGCL) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person or entity in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person or entity with respect to any acquisition proposal or acquisition inquiry (other than to inform such person or entity of the non-solicitation covenants in the merger agreement); |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement, as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101); or |
• | resolve or publicly propose to take any of the foregoing actions. |
• | withdraw or modify in a manner adverse to Synopsys, or permit the withdrawal or the modification in a manner adverse to Synopsys of, the Ansys board recommendation; |
• | recommend the approval, acceptance or adoption of, or approve, endorse, accept or adopt, any acquisition proposal; |
• | approve or recommend, or cause or permit Ansys or any of its subsidiaries to execute or enter into, any letter of intent, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar document or contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve, agree or publicly propose, or permit Ansys or any of its subsidiaries, or any of its or their respective representatives, to agree or publicly propose, to take any of the actions contemplated in any of the preceding bullets. |
• | by the mutual written consent of Synopsys and Ansys; |
• | by either Synopsys and Ansys if the merger has not been completed by 11:59 p.m. (California time) on the end date (as it may be extended in accordance with the merger agreement) (however, a party is not permitted to terminate the merger agreement on such basis if the failure to complete the merger by the end date is primarily attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time in breach of such party’s obligations); |
• | by either Synopsys or Ansys if: (i) a governmental body in any specified jurisdiction has issued a final and nonappealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger; or (ii) there has been any applicable legal requirement enacted, enforced or deemed applicable to the merger by any governmental body in any specified jurisdiction that would make completion of the merger illegal; |
• | by either Synopsys or Ansys upon a no stockholder approval event (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117); |
• | by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event has occurred; |
• | by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into an alternative acquisition agreement, subject to compliance with certain obligations under the merger agreement; or |
• | by either Synopsys or Ansys if, subject to certain exceptions, (i) any of the other party’s representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement or became inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that the closing condition relating to the accuracy of such other party’s representations and warranties would not be satisfied; or (ii) any of the other party’s covenants or obligations contained in the merger agreement was breached such that the closing condition relating to the performance by such other party of its covenants would not be satisfied. |
• | (i) by Synopsys or Ansys because the merger has not been completed by the end date (prior to the satisfaction of the stockholder approval condition (as defined in “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114) or upon the occurrence of the no stockholder approval event; (ii) at or prior to the time of the termination of the merger agreement, but on or after the date of the merger agreement, an acquisition proposal has been publicly disclosed, announced, commenced, submitted or made and such acquisition proposal has not been publicly withdrawn at least 10 calendar days prior to the special meeting (or, in the case of a termination because the merger has not been completed by the end date, an acquisition proposal otherwise exists and has not been withdrawn); and (iii) within 12 months after the date of termination of the merger agreement, an acquisition transaction (whether or not relating to such acquisition proposal) is completed or a definitive agreement providing for an acquisition transaction (whether or not related to such acquisition proposal) is executed; provided, however, that, for purposes of clause (iii) above, all references to “15%” and “85%” in the definition of “acquisition transaction” will be deemed to be references to “50%”; or |
• | (i) by Synopsys, due to the occurrence of a triggering event; (ii) by Synopsys or Ansys, at any time after the occurrence of a triggering event, because the special meeting has been held and completed but |
• | by Synopsys or Ansys as a result of (i) a regulatory proceeding (as defined in “The Merger Agreement—Regulatory Approvals and Related Matters”) brought by a governmental body under any applicable antitrust or competition legal requirement or any applicable foreign investment law in any specified jurisdiction resulting in a final and non-appealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger or (ii) the enactment, enforcement or deemed applicability of any legal requirement to the merger by any governmental body in a specified jurisdiction that would make the completion of the merger illegal; or |
• | by Synopsys or Ansys because the merger has not been completed by the end date and, at the time of termination, all the closing conditions set forth in the merger agreement (other than those conditions that by their terms are to be satisfied at the closing) have been satisfied or waived, other than the HSR waiting period condition, the foreign regulatory waiting period condition, the governmental authorization condition and the no restraint condition (in which case, solely in connection with any applicable antitrust law or regulation or foreign investment law in the specified jurisdictions) (each as defined in “The Merger Agreement—Conditions to Completion of the Merger” beginning on page 114). |
| | Synopsys Common Stock | | | Ansys Common Stock | | | Implied Per Share Value of Merger Consideration | |
December 21, 2023 | | | $559.96 | | | $303.16 | | | $390.19 |
January 12, 2024 | | | $494.40 | | | $346.48 | | | $367.57 |
April 9, 2024 | | | $568.99 | | | $344.50 | | | $393.30 |
• | each company may experience negative reactions from the financial markets, including negative impacts on its stock price; |
• | each company may experience negative reactions from its customers, distributors, suppliers and strategic partners; |
• | current and prospective employees of Synopsys and Ansys may experience uncertainty about their future roles with the combined company following the merger, which might adversely affect Synopsys’ or Ansys’ abilities to retain or attract key managers and other employees; |
• | each company will be required to pay their respective costs relating to the merger, such as financial advisory, legal, financing and accounting costs and associated fees and expenses, whether or not the merger is completed; |
• | the merger agreement places certain restrictions on the conduct of each company’s business before completion of the merger and such restrictions, the waiver of which is subject to the consent of the other company, which may prevent Synopsys or Ansys from taking certain other specified actions during the pendency of the merger (see the section entitled “The Merger Agreement—Interim Operations of Synopsys and Ansys” beginning on page 98 for a description of the restrictive covenants applicable to Synopsys and Ansys); and |
• | matters relating to the merger (including integration planning) will require substantial commitments of time and resources by Synopsys’ senior management and Ansys’ senior management, which otherwise could have been devoted to day-to-day operations or to other opportunities that may have been beneficial to Synopsys or Ansys, as applicable, as an independent company. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry (including by approving any transaction, or approving any person (other than Synopsys and its affiliates) becoming an “interested stockholder,” for purposes of Section 203 of the DGCL) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry; |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve or publicly propose to take any of the actions described in the preceding bullets. |
• | combining the companies’ operations and corporate functions; |
• | combining the businesses of Synopsys and Ansys and meeting the capital requirements of Synopsys following the merger, in a manner that permits Synopsys to achieve any cost savings or revenue synergies anticipated to result from the merger, the failure of which would result in the anticipated benefits of the merger not being realized in the time frame currently anticipated or at all; |
• | integrating personnel and related HR systems and benefits; |
• | integrating the companies’ technologies; |
• | integrating and unifying the offerings and services available to customers; |
• | identifying and eliminating redundant and underperforming functions and assets; |
• | harmonizing the companies’ operating practices, employee development and compensation programs, internal controls and other policies, procedures and processes; |
• | maintaining existing agreements with customers, distributors, suppliers and vendors and avoiding delays in entering into new agreements with prospective customers, distributors, suppliers and vendors; |
• | addressing possible differences in business backgrounds, corporate cultures and management philosophies; |
• | consolidating the companies’ administrative and information technology infrastructure; |
• | coordinating distribution and marketing efforts; |
• | managing the movement of certain positions to different locations; |
• | coordinating geographically dispersed organizations; and |
• | effecting actions that may be required in connection with obtaining the required regulatory approvals. |
• | increasing its vulnerability to changing economic, regulatory and industry conditions; |
• | limiting its ability to compete and its flexibility in planning for, or reacting to, changes in its business and the industry; |
• | placing the combined company at a competitive disadvantage compared to its competitors with less indebtedness; |
• | limiting its ability to execute share repurchase programs; |
• | limiting its ability to borrow additional funds in the future to fund growth, acquisitions, working capital, capital expenditures and other purposes; and |
• | increasing its interest expense and potentially requiring it to dedicate a substantial portion of its cash flow from operations to payments on its debt, thereby reducing the availability of cash to available to fund its working capital and other business needs. |
• | adversely affect the trading price of, or market for, its debt securities; |
• | increase interest expense under its credit facilities; |
• | increase the cost of, and adversely affect its ability to refinance, its existing debt; and |
• | adversely affect its ability to raise additional debt. |
• | cash requirements, capital spending plans, cash flow or financial position; |
• | cash requirements for any future acquisitions; |
• | Synopsys’ stock price; |
• | Synopsys’ desire to maintain or improve the credit ratings on its debt; |
• | restrictions under Delaware law; |
• | leverage covenants in the combined company's credit facilities and indentures and, potentially, the terms of any future indebtedness that the combined company may incur; and |
• | certain limitations on the amount of dividends subsidiaries of the combined company can distribute to Synopsys, as imposed by state law, regulators or agreements. |
• | to adopt the merger agreement, which proposal is referred to as the merger agreement proposal; |
• | to approve, on a non-binding, advisory basis, the merger-related compensation that will or may be paid to Ansys’ named executive officers in connection with the transactions contemplated by the merger agreement, which proposal is referred to as the compensation proposal; and |
• | to approve the adjournment of the special meeting to solicit additional proxies if there are not sufficient votes at the time of the special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Ansys stockholders, which proposal is referred to as the adjournment proposal. |
• | Proposal 1: “FOR” the merger agreement proposal; |
• | Proposal 2: “FOR” the compensation proposal; and |
• | Proposal 3: “FOR” the adjournment proposal. |
Proposal | | | Votes Necessary | |||
Proposal 1 | | | Merger agreement proposal | | | Approval requires the affirmative vote of a majority of the outstanding shares of Ansys common stock entitled to vote on the merger agreement proposal. A failure to vote, a broker non-vote or an abstention will have the same effect as a vote “AGAINST” the merger agreement proposal. |
| | | | |||
Proposal 2 | | | Compensation proposal | | | Approval requires the affirmative vote of a majority of the votes cast at the special meeting on the compensation proposal (meaning the number of votes cast “FOR” this proposal must exceed the votes cast “AGAINST”). A failure to vote, a broker non-vote or an abstention will have no effect on the outcome of the compensation proposal. |
| | | | |||
Proposal 3 | | | Adjournment proposal | | | Approval requires the affirmative vote of a majority of the votes cast at the special meeting on the adjournment proposal (meaning the number of votes cast “FOR” this proposal must exceed the votes cast “AGAINST”). A failure to vote, a broker non-vote or an abstention will have no effect on the outcome of the adjournment proposal. |
• | By the Internet: If you are a stockholder of record, you can vote at www.virtualshareholdermeeting.com/ANSS2024SM and follow the instructions, 24 hours a day, seven days a week. You will need the 16-digit control number included on your proxy card or your paper voting instruction form (if you received a paper copy of the proxy materials). |
• | By Telephone: If you are a stockholder of record, you can vote using a touch-tone telephone by calling 1-800-690-6903 and follow the recorded instructions, 24 hours a day, seven days a week. You will need the 16-digit control number included on your proxy card or your paper voting instruction form (if you received a paper copy of the proxy materials). |
• | By Mail: If you have received a paper copy of the proxy materials by mail, you may complete, sign, date and return by mail the paper proxy card or voting instruction form sent to you in the envelope provided to you with your proxy materials or voting instruction form. |
• | sending a signed written notice of revocation to Ansys’ corporate secretary; |
• | voting again by the Internet or telephone at a later time before the closing of the voting facilities at 11:59 p.m., Eastern Time, on the date before the special meeting; |
• | submitting a properly signed proxy card with a later date; or |
• | attending virtually and voting at the special meeting via the special meeting website. |
• | determined that the merger agreement, the merger and the other transactions contemplated by the merger agreement are fair to, and in the best interests of, Ansys and its stockholders; |
• | approved and declared advisable the merger agreement, the merger and the other transactions contemplated by the merger agreement; |
• | directed the merger agreement be submitted for adoption at a meeting of Ansys stockholders; and |
• | recommended that Ansys stockholders vote in favor of the adoption of the merger agreement. |
• | Premium to Current Equity Price. The merger consideration to be paid by Synopsys of $197.00 in cash and 0.3450 of a share of Synopsys common stock, which implied an equity value of $390.19 per share of Ansys common stock, based on Synopsys’ closing stock price on December 21, 2023, the last full trading day prior to media speculation regarding a potential transaction, would provide Ansys stockholders with the opportunity to receive approximately (1) a 29% premium over the closing price of $303.16 per share of Ansys common stock on December 21, 2023, the last full trading day prior to media speculation regarding a potential transaction and (2) a 35% premium over the 60-day volume weighted average price for the period ending on December 21, 2023. |
• | Liquidity and Certainty of Value. A significant portion of the merger consideration to be paid to Ansys stockholders will consist of cash, which will provide immediate liquidity and certainty of value to Ansys stockholders and will mitigate the risk of any contraction in trading multiples of Synopsys stock during the pendency of the merger, and the remainder of the merger consideration to be paid to Ansys stockholders will consist of freely tradable Synopsys common stock. |
• | Future Appreciation. The merger and the merger consideration offered in connection therewith will provide Ansys stockholders with ownership of approximately 16.5% of the combined company on a pro forma basis and, therefore, allow Ansys stockholders to participate through the stock portion of the consideration in any appreciation in the equity value of Synopsys, including as a result of the synergies expected to result from the merger. |
• | Strategic Benefits. The proposed transaction provides compelling strategic and financial benefits in which Ansys stockholders would participate through the stock portion of the merger consideration, including the expectation of the Ansys board of directors that the transaction will (1) combine Synopsys’ EDA technology with Ansys’ established simulation and analysis capabilities to provide customers a comprehensive, powerful and system-focused approach to innovation, (2) combine highly complementary businesses with significant expansion opportunities, (3) build upon the successful partnership between Synopsys and Ansys dating back to 2017, (4) meaningfully expand the combined company’s total addressable market by 1.5x to $28 billion, (5) increase the combined company’s strong financial position and outlook, (6) generate substantial and sustained free cash flow for the combined company, which will enable rapid de-leveraging, (7) achieve significant cost and revenue synergies and (8) deliver greater opportunities for employee development given the larger organization. |
• | Competitive Process. The proposed transaction was the product of a competitive negotiated process that in the Ansys board of directors’ view represents the best risk-adjusted value attainable among all the parties that had put forward an indication of interest with respect to a combination with Ansys. |
• | Cultural Alignment. The cultural alignment between Ansys and Synopsys, including shared values and commitment to integrity, operational excellence, customer satisfaction, innovation and stockholder value. |
• | Synopsys’ Business Condition and Prospects. The information and discussions with Ansys’ senior management and outside advisors regarding their diligence review of Synopsys’ business, assets, financial condition, results of operations, current business strategy and prospects, including the historical operational and market performance of Synopsys, the size and scale of Synopsys and the expected pro forma effect of the proposed merger on Synopsys. |
• | Business Environment. The current and prospective business environment in which Ansys and Synopsys operate, including international, national and local economic conditions, the competitive and regulatory environment, and the likely effect of these factors on Ansys and Synopsys. |
• | Fairness Opinion. The analyses and presentations of Qatalyst Partners and its oral opinion, subsequently confirmed in writing, to the Ansys board of directors that, as of the date of the opinion, and based upon and subject to the various assumptions, qualifications, limitations and other matters set forth in its written opinion, the merger consideration to be paid to Ansys stockholders pursuant to the merger agreement was fair, from a financial point of view, to Ansys stockholders, as more fully described under the section entitled “The Merger—Opinion of Qatalyst Partners” beginning on page 72 and the full text of the written opinion of Qatalyst Partners, which is attached as Annex B to this proxy statement/prospectus. |
• | Extensive Negotiations. The merger consideration reflected extensive negotiations between Ansys and Synopsys and their respective advisors, and the belief of the Ansys board of directors that the merger consideration represents the best proposal and economic value available to Ansys’ stockholders. |
• | Regulatory Matters. The Ansys board of directors’ view, after consultation with Ansys’ senior management and Skadden, concerning the likelihood that regulatory approvals and clearances necessary to consummate the merger would be obtained. |
• | Terms of the Merger Agreement. The review by the Ansys board of directors with its advisors of the structure of the proposed merger and the financial and other terms of the merger agreement, including the parties’ representations, warranties and covenants, the conditions to their respective obligations to complete the merger and the termination provisions as well as the likelihood of consummation of the proposed transactions and the evaluation of the Ansys board of directors of the likely time period necessary to complete the merger. The Ansys board of directors also considered the following specific aspects of the merger agreement: |
○ | the limited number of closing conditions included in the merger agreement, including the absence of a financing condition or similar contingency that is based on Synopsys’ ability to obtain financing, the exceptions to the events that would constitute a material adverse effect on Ansys for purposes of the merger agreement, as well as the likelihood of satisfaction of all conditions to completion of the transactions; |
○ | the ability of Ansys stockholders to approve or reject the merger by voting on the adoption of the merger agreement; |
○ | the requirement to use reasonable best efforts to obtain approvals or clearances by applicable governmental authorities, including by divesting assets, holding assets separate or otherwise taking any other action that would limit Ansys’ or Synopsys’ freedom of action, except to the extent that such action would, individually or in the aggregate, (1) involve the divestment of businesses, product lines or assets representing, individually or in the aggregate, more than $200 million of revenue generated during fiscal year 2023 or (2) involve any limitation on the freedom of action of Synopsys, Ansys or their respective subsidiaries that would, individually or in the aggregate, reasonably be expected to have a material impact on the combined company, taken as a whole (including any impact on expected synergies), measured on a scale relative to the size of Ansys and its subsidiaries, taken as a whole, prior to the merger; |
○ | the fact that the Ansys board of directors has the right, after complying with specified covenants and prior to the Ansys stockholder approval being obtained, to change its recommendation to the Ansys stockholders that they vote in favor of the adoption of the merger agreement if the Ansys board of directors determines in good faith after consultation with Ansys’ outside legal counsel and financial advisors, that as a result of a superior proposal or certain intervening events the failure to change its recommendation would be inconsistent with its fiduciary duties to Ansys’ stockholders under applicable Delaware law; |
○ | the requirement that, in the event of the termination of the merger agreement under certain circumstances, Synopsys will pay Ansys a termination fee of $1.5 billion; and |
○ | Ansys’ right to terminate the merger agreement under certain circumstances, including in order to accept and enter into a definitive agreement with respect to an unsolicited superior offer in certain circumstances, subject to providing Synopsys an opportunity to match such offer prior to taking such action and payment to Synopsys of a termination fee of $950 million if the merger agreement is so terminated, which amount the Ansys board of directors believes to be reasonable under the circumstances, taking into account the range of such termination fees in similar transactions. |
• | the risk that Synopsys’ financial performance may not meet Ansys’ expectations, including any contraction of trading multiples of Synopsys stock during the pendency of the transaction; |
• | the impact of external factors on Synopsys’ financial performance and/or trading multiples, including changes in regulation and other macroeconomic and political factors; |
• | the difficulties and management challenges inherent in completing the merger and integrating the business, operations and workforce of Ansys and Synopsys and the risk of not capturing all the anticipated synergies and the risk that other anticipated benefits of the merger might not be realized; |
• | the amount of time it could take to complete the merger, including that completion of the merger depends on factors outside of Ansys’ or Synopsys’ control, and the risk that the pendency of the merger for an extended period of time following the announcement of the execution of the merger agreement could have an adverse impact on Ansys or Synopsys, including their respective customer, supplier and other business relationships; |
• | the possible diversion of management attention for an extended period of time during the pendency of the merger; |
• | the risk that, despite the retention efforts of Ansys and Synopsys prior to the consummation of the merger, Ansys and Synopsys may lose key personnel; |
• | the provisions of the merger agreement that prohibit Ansys from soliciting other acquisition proposals and the potential payment to Synopsys by Ansys of a termination fee of $950 million, as described in the section entitled “The Merger Agreement—Termination Fees” beginning on page 119; |
• | that certain provisions of the merger agreement, including the $950 million termination fee, may have the effect of discouraging alternative proposals to acquire Ansys; |
• | the risk that if Synopsys fails to complete the merger as a result of a breach of the merger agreement in certain circumstances, remedies may be limited to the termination fee of $1.5 billion, as described in the section entitled “The Merger Agreement—Termination Fees” beginning on page 119, which may be inadequate to compensate Ansys for the damage caused, and if available, other rights and remedies may be expensive and difficult to enforce, and the success of any such action may be uncertain; |
• | the potential for litigation relating to the proposed merger and the associated costs, burden and inconvenience involved in defending those proceedings; |
• | the restrictions in the merger agreement on the conduct of Ansys’ business during the period between execution of the merger agreement and the consummation of the merger, including that Ansys must conduct its business only in the ordinary course, subject to specific limitations, and a prohibition on Ansys entering into mergers and acquisitions, which could negatively impact Ansys’ ability to pursue certain business opportunities or strategic transactions; |
• | the risk that regulatory agencies may delay, object to and challenge the merger or may impose terms and conditions in order to resolve those objections that adversely affect the financial results of Ansys or Synopsys; see the section entitled “The Merger—Regulatory Approvals and Related Matters” beginning on page 85; |
• | the treatment of the merger consideration to be received by Ansys stockholders as taxable for U.S. federal income and other tax purposes; |
• | the fact that the exchange ratio for the stock component of the merger consideration is fixed under the merger agreement, meaning that the value of the merger consideration, consisting of $197.00 in cash and 0.3450 of a share of Synopsys common stock for each share of Ansys common stock, upon consummation of the merger might be more or less than or the same as the value of such consideration on the date of the execution of the merger agreement; and |
• |
• | adding: |
(a) | the implied net present value of the estimated future unlevered free cash flows (which are referred to as the “UFCF”) of Ansys, based on each of Management Case 1, Management Case 2 and Management Case 3, as applicable, for the calendar year 2024 through calendar year 2032 (which implied present value was calculated using a range of discount rates of 10.5% to 13.0%, based on an estimated weighted average cost of capital for Ansys); |
(b) | the implied net present value of a corresponding terminal value of Ansys, calculated by multiplying Ansys’ estimated UFCF in fiscal year 2033 of approximately $3,178 million, $2,640 million and $1,843 million, based on each of Management Case 1, Management Case 2 and Management Case 3, as applicable, by a range of fully diluted enterprise value to |
(c) | the cash and cash equivalents of Ansys as of December 31, 2023, as provided by management of Ansys, as adjusted for Ansys’ anticipated acquisition of a minority ownership interest in Humanetics Innovative Solutions, Inc.; |
• | subtracting the face value of Ansys’ outstanding debt as of December 31, 2023 (including unfunded pension obligations), as provided by Ansys’ management; and |
• | dividing the resulting amount by the number of fully diluted shares of Ansys common stock outstanding (calculated using the treasury stock method, taking into account the Ansys RSUs, Ansys PSUs, in-the-money options, and other equity awards as of January 11, 2024), as provided by management of Ansys, with each of the above-referenced estimated future UFCFs and terminal value having also been adjusted for the degree of estimated dilution to current stockholders through each respective applicable period (approximately 0.5% to 1.0% annually throughout the projection period) due to the estimated net effects of equity issuances and cancellations related to future equity compensation, based on estimates of future dilution provided by management of Ansys. |
Forecast Scenario | | | Implied Value Per Share of Ansys common stock ($) |
Management Case 1 | | | 303.33 – 496.04 |
Management Case 2 | | | 257.84 – 418.39 |
Management Case 3 | | | 160.25 – 266.24 |
Selected Engineering Software Companies | | | CY2024E LFCF Multiple |
Synopsys, Inc.(1) | | | 56.5x |
Cadence Design Systems, Inc. | | | 47.0x |
Altair Engineering Inc.(2) | | | 46.6x |
Altium Limited | | | 43.4x |
Nemetschek SE | | | 39.8x |
Bentley Systems, Incorporated | | | 39.3x |
Autodesk, Inc. | | | 36.7x |
Dassault Systèmes SE | | | 36.2x |
Aspen Technology, Inc. | | | 30.0x |
PTC Inc. | | | 27.9x |
Selected Profitable Software Companies | | | CY2024E LFCF Multiple |
ServiceNow Inc. | | | 46.3x |
Workday, Inc. | | | 38.4x |
Palo Alto Networks, Inc. | | | 36.4x |
Adobe Inc. | | | 31.3x |
SAP SE | | | 28.7x |
Oracle Corporation | | | 27.6x |
Salesforce, Inc. | | | 25.5x |
DocuSign, Inc.(3) | | | 18.5x |
ZoomInfo Technologies Inc. | | | 14.4x |
(1). | Fully diluted equity value based on per share price of $551.62, which reflects closing share price of $559.96 as of December 21, 2023, adjusted by subsequent average share price performance to January 12, 2024 of selected technical software companies including Cadence, Autodesk, PTC, Altium, Nemetschek, Bentley and Dassault. |
(2). | Fully diluted equity value reflects closing share price as of December 21, 2023, the last trading day prior to the publication of a Bloomberg article reporting on a potential sale of Ansys. |
(3). | Fully diluted equity value reflects closing share price as of December 14, 2023, the last trading day prior to rumors in the press that DocuSign was exploring a sale process. |
Equity Value / CY2024E LFCF Multiple | | | Implied Value Per Share of Ansys common stock ($) |
Management Case 1 | | | 212.98 – 340.71 |
Management Case 2 | | | 204.70 – 327.46 |
Management Case 3 | | | 198.32 – 317.24 |
Street Case | | | 210.20 – 336.26 |
Announcement Date | | | Target | | | Acquiror | | | NTM LFCF MULTIPLE |
11/14/16 | | | Mentor Graphics Corporation | | | Siemens Industry, Inc. | | | 46.6x |
08/19/21 | | | Inovalon Holdings, Inc. | | | Nordic Capital | | | 41.5x |
12/07/21 | | | Mimecast Limited | | | Permira Holdings Limited | | | 40.6x |
12/12/22 | | | Coupa Software Incorporated | | | Thoma Bravo | | | 39.3x |
12/21/20 | | | RealPage, Inc. | | | Thoma Bravo | | | 37.8x |
10/28/18 | | | Red Hat Inc. | | | IBM Corp | | | 33.8x |
09/21/22 | | | AVEVA Group plc | | | Schneider Electric SE | | | 31.9x |
09/21/23 | | | Splunk Inc. | | | Cisco Systems Inc. | | | 29.3x |
05/04/22 | | | Black Knight, Inc. | | | Intercontinental Exchange, Inc. | | | 28.2x |
03/06/18 | | | CommerceHub, Inc. | | | GTCR and Sycamore Partners | | | 26.8x |
02/02/15 | | | Advent Software, Inc. | | | SS&C Technologies Holdings, Inc. | | | 24.1x |
12/20/21 | | | Cerner Corporation | | | Oracle Corporation | | | 23.9x |
04/07/15 | | | Informatica Corp | | | Permira Holdings Limited | | | 22.1x |
09/19/16 | | | Infoblox Inc. | | | Vista Equity Partners | | | 21.9x |
06/15/15 | | | Dealertrack Technologies, Inc. | | | Cox Automotive, Inc. | | | 20.0x |
08/05/21 | | | Cornerstone OnDemand, Inc. | | | Clearlake Capital Group, L.P. | | | 18.4x |
01/31/22 | | | Citrix Systems, Inc. | | | Vista Equity Partners Management, LLC and Evergreen Coast Capital Corp. | | | 17.9x |
05/26/22 | | | VMware, Inc. | | | Broadcom Inc. | | | 16.6x |
07/01/11 | | | Blackboard Inc. | | | Providence Equity Partners L.L.C. | | | 16.2x |
12/15/14 | | | Riverbed Technology, Inc. | | | Thoma Bravo | | | 15.5x |
11/07/21 | | | McAfee Corp. | | | Advent, Permira, Crosspoint Capital, CPP Investments, GIC and ADIA | | | 14.5x |
12/17/19 | | | LogMeIn, Inc. | | | Francisco Partners Management, L.P. | | | 14.0x |
07/07/16 | | | AVG Technologies N.V. | | | Avast Software B.V. | | | 13.2x |
07/02/12 | | | Quest Software, Inc. | | | Dell Inc. | | | 12.8x |
05/06/13 | | | BMC Software Inc. | | | Bain Capital, Golden Gate Capital, GIC Special Investments Pte Ltd., and Insight Venture Partners | | | 10.6x |
11/02/15 | | | Neustar, Inc. | | | Golden Gate Capital | | | 5.9x |
06/12/19 | | | Medidata Solutions, Inc. | | | Dassault Systèmes SE | | | - |
(in millions) | | | FY2024E | | | FY2025E | | | FY2026E | | | FY2027E | | | FY2028E | | | FY2029E | | | FY2030E | | | FY2031E | | | FY2032E | | | FY2033E |
Management Case 1 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,567 | | | $2,942 | | | $3,406 | | | $3,938 | | | $4,556 | | | $5,262 | | | $6,067 | | | $6,983 | | | $8,024 | | | $9,203 |
Revenue | | | $2,510 | | | $2,890 | | | $3,367 | | | $3,892 | | | $4,503 | | | $5,201 | | | $5,997 | | | $6,902 | | | $7,931 | | | $9,097 |
Unlevered Free Cash Flow(2) | | | $795 | | | $979 | | | $1,159 | | | $1,342 | | | $1,558 | | | $1,804 | | | $2,084 | | | $2,404 | | | $2,766 | | | $3,178 |
Management Case 2 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,534 | | | $2,871 | | | $3,278 | | | $3,730 | | | $4,245 | | | $4,822 | | | $5,468 | | | $6,185 | | | $6,982 | | | $7,869 |
Revenue | | | $2,491 | | | $2,838 | | | $3,265 | | | $3,716 | | | $4,228 | | | $4,803 | | | $5,447 | | | $6,161 | | | $6,955 | | | $7,839 |
Unlevered Free Cash Flow(2) | | | $766 | | | $929 | | | $1,082 | | | $1,237 | | | $1,417 | | | $1,606 | | | $1,825 | | | $2,068 | | | $2,339 | | | $2,640 |
Management Case 3 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,508 | | | $2,767 | | | $3,054 | | | $3,332 | | | $3,615 | | | $3,897 | | | $4,182 | | | $4,466 | | | $4,747 | | | $5,027 |
Revenue | | | $2,480 | | | $2,736 | | | $3,008 | | | $3,282 | | | $3,560 | | | $3,838 | | | $4,118 | | | $4,398 | | | $4,676 | | | $4,951 |
Unlevered Free Cash Flow(2) | | | $743 | | | $881 | | | $1,005 | | | $1,115 | | | $1,229 | | | $1,346 | | | $1,466 | | | $1,589 | | | $1,716 | | | $1,843 |
(1) | Annual Contract Value (“ACV”) is a key performance metric for Ansys and is useful to investors in assessing the strength and trajectory of the business. ACV is a supplemental metric to help evaluate the annual performance of the business. Over the life of a customer, ACV equals the total value realized from a customer. ACV is not impacted by the timing of license revenue recognition. ACV is used by Ansys’ management in financial and operational decision-making and in setting sales targets used for compensation. ACV is not a replacement for, and should be viewed independently of, GAAP revenue and deferred revenue as ACV is a performance metric and is not intended to be combined with any of these items. There is no GAAP measure comparable to ACV. |
(2) | Unlevered Free Cash Flow is a supplemental non-GAAP measure used by Ansys to further evaluate performance of the business. Unlevered Free Cash Flow is calculated as unlevered operating cash flow less capital expenditures. Unlevered operating cash flow is defined as operating cash flow (a GAAP measure) excluding cash paid for interest, net of the associated tax benefit. |
• | the merger will have been completed; |
• | the absence of a material adverse effect on Ansys; |
• | the repayment and termination in full of the Ansys credit agreement; |
• | payment of fees and expenses due under the term loan credit agreement; |
• | delivery of certain historical and pro forma financial information of Synopsys and Ansys; |
• | certain specified representations and warranties under the term loan credit agreement and the merger agreement being true and correct in all material respects; and |
• | certification of the solvency of Synopsys and its subsidiaries on a consolidated basis and certain other customary documentation requirements for similar facilities. |
• | amends the applicable margin used to determine the interest that accrues on loans and the facility fee payable under the revolving credit facility to be based on the credit ratings of Synopsys; |
• | amends the financial covenant thresholds under the financial covenant in the revolving credit facility requiring us to maintain a maximum consolidated leverage ratio; and |
• | amends certain conditions to borrowing, other non-financial covenants and events of default. |
• | corporate organization and similar corporate matters, including corporate standing; |
• | qualification to do business under applicable law and corporate power; |
• | capital structure and equity securities; |
• | the timely filing of all documents required to be filed with the SEC since January 1, 2021, and the content and preparation of financial statements; |
• | absence of certain changes, events and actions between, with respect to Synopsys, October 28, 2023, and with respect to Ansys, September 30, 2023, and the date of the merger agreement; |
• | absence of undisclosed liabilities; |
• | compliance with legal requirements; |
• | possession of permits, licenses, registrations and other qualifications and authorizations from governmental bodies and the making of filings required under applicable legal requirements; |
• | legal proceedings and orders; |
• | tax matters; |
• | authority to enter into and to perform obligations under the merger agreement and to complete the transactions contemplated thereby; |
• | the completion of the transactions contemplated by the merger agreement not contravening applicable organizational documents or laws; legal requirements; orders or governmental authorizations; contracts and permits or licenses, registrations and other qualifications; |
• | required governmental approvals for the completion of the transactions contemplated by the merger agreement, including the merger; |
• | accuracy of information supplied for inclusion in this proxy statement/prospectus; and |
• | absence of other representations and warranties. |
• | subsidiaries; |
• | the provision of and compliance with, organizational, governing and similar corporate documents; |
• | title to tangible assets ownership; |
• | owned real property, validity of leases and absence of subleases and licenses granting use of leased real property to another person or entity and adequacy of equipment and other tangible assets; |
• | intellectual property; |
• | material contracts, including the validity and effectiveness of those contracts and the absence of material breaches of or defaults under those contracts; |
• | matters relating to Ansys’ products; |
• | relations with major customers and suppliers; |
• | employment and labor matters; |
• | employee benefit plans; |
• | environmental matters; |
• | insurance; |
• | recommendation by the Ansys board of directors to Ansys stockholders regarding the merger agreement and the merger; |
• | anti-takeover statutes and regulations and absence of a stockholder rights plan; |
• | stockholder vote required for adoption or approval of the merger agreement and approval of the merger; |
• | opinion of Ansys’ financial advisor; |
• | advisors’ fees; and |
• | absence of related person transactions. |
• | absence of: (a) ownership by Synopsys, Merger Sub or any of their respective controlled affiliates of shares of Ansys common stock or any other options, warrants or other rights to acquire share of common stock of Ansys and (b) ownership as defined under Section 203 of the DGCL by Synopsys, Merger Sub or any of their respective controlled affiliates of Ansys capital stock within the three years of the date of the merger agreement; |
• | capitalization and absence of prior operations of Merger Sub; |
• | availability of financing and the sufficiency of the aggregate net proceeds from the debt financing (when funded in accordance with the debt commitment letter), together with all other sources of cash or other financing sources available to Synopsys, for the satisfaction of Synopsys’ payment obligations under the merger agreement; and |
• | solvency. |
• | changes in economic conditions, including any changes affecting financial, credit, foreign exchange or capital market conditions in the United States or in other locations in which the party and its subsidiaries have material operations; except that this exception will not apply to the extent that such change, development, event or circumstance has had a disproportionate effect on the party and its subsidiaries as compared to other companies in the industries in which the party and its subsidiaries operate, in which case only the incremental disproportionate adverse impact of such change, development, event or circumstance will be taken into account for the purposes of determining whether a material adverse effect has occurred or would reasonably be expected to occur; |
• | changes in economic conditions that generally affect the industries in which the party and its subsidiaries operates; except that this exception will not apply to the extent that such change, development, event or circumstance has had a disproportionate effect on that party and its subsidiaries as compared to other companies in the industries in which that party and its subsidiaries operate, in which case only the incremental disproportionate adverse impact of such change, development, event or circumstance will be taken into account for the purposes of determining whether a material adverse effect has occurred or would reasonably be expected to occur; |
• | changes in the stock price or trading volume of the party’s common stock (it being understood, however, that the facts or circumstances giving rise to any such change in stock price or trading volume that are not otherwise excluded from the definition of “material adverse effect” may be taken into account in determining whether a material adverse effect on that party has occurred or would reasonably be expected to occur); |
• | the failure of the party to meet internal or securities analysts’ published projections of earnings or revenues (it being understood, however, that the facts or circumstances giving rise to any such failure that are not otherwise excluded from the definition of “material adverse effect” may be taken into account in determining whether a material adverse effect on that party has occurred or would reasonably be expected to occur); |
• | changes that are effected after the date of the merger agreement in legal requirements, or changes that are effected after the date of the merger agreement in GAAP or other accounting standards (or the interpretation thereof); except that this exception will not apply to the extent that such change, development, event or circumstance has had a disproportionate effect on the party and its subsidiaries as compared to other companies in the industries in which that party and its subsidiaries operate, in which case only the incremental disproportionate adverse impact of such change, development, event or circumstance will be taken into account for the purposes of determining whether a material adverse effect has occurred or would reasonably be expected to occur; |
• | changes in political conditions in the U.S. or any other country in the world in which the party and its subsidiaries have material operations, or acts of war, sabotage, acts of armed hostility or terrorism (including cyber terrorism) that occur in the U.S. or in other locations in which that party and its subsidiaries have material operations, or the worsening of such conditions existing as of the date of the merger agreement; except that this exception will not apply to the extent that such change, development, event or circumstance has had a disproportionate effect on the party and its subsidiaries as compared to other companies in the industries in which that party and its subsidiaries operate, in which case only the incremental disproportionate adverse impact of such change, development, event or circumstance will be taken into account for the purposes of determining whether a material adverse effect has occurred or would reasonably be expected to occur; |
• | acts of God, earthquakes, hurricanes, tsunamis, tornados, floods, mudslides, wild fires or other natural disasters, weather conditions, epidemics, pandemics or disease outbreaks, cyberattacks, data breaches or other force majeure events, or the worsening of such conditions existing as of the date of the merger agreement; except that this exception will not apply to the extent that such change, development, event or circumstance has had a disproportionate effect on the party and its subsidiaries as compared to other companies in the industries in which that party and its subsidiaries operate, in which case only the incremental disproportionate adverse impact of such change, development, event or circumstance will be taken into account for the purposes of determining whether a material adverse effect has occurred or would reasonably be expected to occur; |
• | the negotiation, execution, delivery, announcement or pendency of the merger agreement or the anticipated completion of the merger, including by reason of the identity of the party and changes in relationships with or losses of customers, suppliers or other business partners or employees resulting from the foregoing (except that such exceptions will not apply with respect to certain specified representations and warranties); |
• | any stockholder class action or derivative litigation commenced against the party after the date of the merger agreement and arising from allegations of breach of fiduciary duty of that party’s directors relating to their approval of the merger agreement or from allegations of false or misleading public disclosure by the party with respect to the merger agreement; or |
• | any action taken or failure to take action, in each case, that the party has expressly approved in writing after the date of the merger agreement. |
• | (a) declare, accrue, set aside, establish a record date for or pay any dividend or other distribution (whether in cash, stock or otherwise) in respect of its shares of capital stock or other securities, except for cash dividends or distributions declared, accrued, set aside or made by any direct or indirect wholly owned subsidiary of Ansys to Ansys or one of its other wholly owned subsidiaries, (b) pledge or encumber any shares of its capital stock or other securities; (c) modify the terms of any shares of its capital stock or other equity or voting interests; or (d) repurchase, redeem or otherwise reacquire any of its shares of capital stock or other securities, other than (i) pursuant to the terms of the Ansys equity plans, award agreements or contracts evidencing Ansys equity awards or the ESPP, (ii) the acquisition of equity awards in connection with the forfeiture of such awards, (iii) shares of Ansys common stock accepted as payment for the exercise price of Ansys options in accordance with the terms of such Ansys options and Ansys equity plans in effect on the date of the merger agreement or (iv) for withholding taxes incurred in connection with the exercise, vesting or settlement of Ansys equity award in accordance with the terms of the applicable Ansys equity award or the ESPP as in effect on the date of the merger agreement; |
• | sell, issue, grant or authorize the sale, issuance or grant of: (a) any of its capital stock or any other security; (b) any option, stock appreciation right, restricted stock unit, deferred stock unit, market stock unit, performance stock unit, restricted stock award or other equity-based compensation award (whether payable in cash, stock or otherwise), call, warrant or right to acquire any its capital stock or any other security; or (c) any instrument convertible into or exchangeable for any of its capital stock or any other security (except that Ansys may issue shares of Ansys common stock (i) upon the exercise of, or the vesting, settlement or delivery of shares pursuant to, Ansys equity awards in accordance with their terms, (ii) pursuant to the ESPP in accordance with its terms or (iii) in connection with any transaction between Ansys or one of its subsidiaries, on the one hand, and another one of Ansys’ subsidiaries, on the other hand. |
• | except for actions required pursuant to the terms of any Ansys employee benefit plan or collective bargaining agreement, labor agreement, works council agreement or any similar agreement with any labor organization, union, works council or other labor representative representing any employee of Ansys or its subsidiaries (a “collective bargaining agreement”), amend or waive any of its rights under, or accelerate the vesting under, any provision of any of the Ansys equity plan or any provision of any contract evidencing any Ansys equity award, or otherwise materially modify any of the terms of any outstanding Ansys equity award; |
• | amend or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational documents, or effect or become a party to any liquidation, dissolution, restructuring, recapitalization, reclassification of shares, stock split, reverse stock split, division or subdivision of shares, consolidation of shares or similar transaction; |
• | acquire (by merger, consolidation, business combination, operation of law, acquisition of stock, other equity interests or assets, formation of a joint venture or otherwise) (a) any equity interest in any other entity (other than equity securities of publicly traded entities acquired solely for cash management or passive investment purposes in the ordinary course of business) or (b) any business or assets of any other entity, unless the acquisition is (i) of supplies or materials in the ordinary course of business consistent with past practice, (ii) a transaction solely between or among Ansys or one of its subsidiaries, on the one hand, and another one of Ansys’ subsidiaries, on the other hand, (iii) of intellectual property rights pursuant to non-exclusive licenses in the ordinary course of business consistent with past practice or (iv) a capital expenditure permitted by the merger agreement (and, without limiting the foregoing, Ansys will not, and will not permit or cause any of its subsidiaries to, acquire any business or assets of another person or entity, whether by merger, consolidation, purchase of property or assets (including equity interests) or otherwise, if the taking of such action would reasonably be expected (at the time such action is taken) to (1) prevent, materially delay or impede the completion of the merger or (2) cause any of the HSR waiting period condition, the foreign regulatory waiting period condition or the governmental authorization condition not be satisfied prior to the end date; |
• | make any capital expenditures or incur any obligations or liabilities in respect thereof during any fiscal year in excess of the scheduled amount with respect to such fiscal year; |
• | (a) enter into or become bound by any contract that would constitute a material contract if in effect as of the date of the merger agreement, (b) renew, extend, amend in any material respect, or waive or exercise any material right or remedy under, any material contract, or (c) voluntarily terminate any material contract, in each case, other than in the ordinary course of business consistent with past practices (but this will not prohibit or restrict Ansys and its subsidiaries from entering into or renewing, extending or amending any contract to the extent such entry, renewal, extension or amendment implements a transaction or action that is specifically permitted by another interim operating covenant; |
• | enter into, amend or become bound by certain types of contracts; |
• | (a) acquire, lease or license any real property from any other person or entity or (b) sell or otherwise dispose of, or lease or license, any asset (other than intellectual property rights with a value in excess of $5 million individually or $10 million in the aggregate to any other person or entity (except, in each case, for (i) obsolete assets disposed of by Ansys in the ordinary course of business consistent with past practices; (ii) the renewal of any lease upon the expiration thereof for a renewal term of no greater than 12 months, (iii) any transaction solely between or among Ansys or one of its subsidiaries, on the one hand, and one of Ansys’ subsidiaries, on the other hand, or (iv) in the case of any real property, renewals or extensions that become automatically effective unless a party thereto provides prior notice of an intention not to renew or extend); |
• | (a) incur or assume any indebtedness for borrowed money or issue any debt securities, except (i) for loans or advances owed solely between or among Ansys and any of its wholly-owned subsidiaries; (ii) for obligations incurred pursuant to business credit cards in the ordinary course of business and consistent with past practices; (iii) pursuant to the Ansys credit agreement; or (iv) pursuant to letters of credit, working capital loans or factoring of receivables in the ordinary course of business; (b) assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other person or entity, except (i) with respect to obligations of Ansys and its wholly-owned subsidiaries; or (ii) for obligations under the Ansys credit agreement; (c) make any loan, advance or capital contribution to, or investment in, any other person or entity, except for (i) extensions of credit to customers in the ordinary course of business and consistent with past practices; (ii) advances to directors, officers and other employees, in each case in the ordinary course of business and consistent with past practices; or (iii) loans or advances between subsidiaries of Ansys or between Ansys and its subsidiaries and capital contributions in wholly-owned subsidiaries of Ansys; (d) mortgage, pledge or otherwise encumber any assets, tangible or intangible or create any encumbrance thereon, except for permitted encumbrances; or (e) other than in the ordinary course of business consistent with past practices, enter into any currency or interest rate hedging arrangements, swap arrangements or similar arrangements; |
• | (a) except as required pursuant to the terms of any existing collective bargaining agreement, enter into any material collective bargaining agreement with any labor organization, union, works council or similar employee representative body, (b) except for actions required pursuant to the terms of any Ansys employee benefit plan or collective bargaining agreement, establish, adopt, enter into, amend or terminate any material Ansys employee benefit plan (including employment agreements or executive compensation plans, programs, agreements or arrangements, change in control plans, programs or arrangements) that would be a material Ansys employee benefit plan (including employment agreements or executive compensation plans, programs, agreements or arrangements, change in control plans, programs or arrangements) if it was in existence on the date of the merger agreement or (c) except for actions required pursuant to the terms of any Ansys employee benefit plan or collective bargaining agreement, pay, or make any new commitment to pay, any bonus, cash incentive payment or profit-sharing or similar payment to, or increase or make any commitment to increase the amount of the wages, salary, commissions, fringe benefits or other compensation (including severance but excluding (i) equity-based compensation, which is addressed in other covenants) (ii) benefits and fringe benefits payable or provided in the ordinary course of business consistent with past practices to any of its officers or other employees and (iii) de minimis amounts payable or provided in the ordinary course of business consistent with past practice) to, any of its officers or other employees); |
• | (a) hire or terminate (other than for cause) any employee at the level of Vice President (Grade M6) or above; or (b) promote any employee to the level of Vice President (Grade M6) or above; except, in the case of each of clauses “(a)” and “(b)”: (i) to fill a position at such level that is open as of, or is vacated on or after the date of the merger agreement and (ii) only to the extent such employee is entitled to compensation (cash and equity) and health and welfare benefits that are individually no more favorable than the compensation (cash and equity) and health and welfare benefits than were provided to the employee whose position is being filled; |
• | except as required by GAAP or, in the case of an Ansys subsidiary organized and operating outside of the United States, other applicable accounting standards: (a) change in any material respect any of its methods of accounting or accounting practices, including with respect to taxes; or (b) revalue or write down any of its assets in excess of $15 million in the aggregate, except in the ordinary course of business consistent with past practice; |
• | (a) make, change, rescind, or adopt any material method of tax accounting or any material tax election; (b) prepare or file any material tax return inconsistent with past practices, unless Ansys delivers to Synopsys a copy of such tax returns at least 30 days before the applicable due date for review and approval (which approval will not be unreasonably withheld, conditioned or delayed); (c) amend any material tax return; (d) settle or otherwise compromise any claim, dispute, notice, audit or assessment relating to an amount of taxes (reduced by any offsetting benefits or credits reasonably expected to be realized in the same tax year) in excess of $5 million, or enter into, cancel or modify any closing or similar agreement relating to an amount of taxes (reduced by any offsetting benefits or credits reasonably expected to be realized in the same tax year) in excess of $5 million; (e) request any material ruling, closing agreement or similar guidance with respect to an amount of taxes (reduced by any offsetting benefits or credits reasonably expected to be realized in the same tax year) in excess of $5 million; or (f) surrender any material right or claim to a refund of taxes; |
• | (a) commence any legal proceeding, other than (i) routine collection or anti-piracy matters in the ordinary course of business and consistent with past practices, or (ii) against Synopsys, or Merger Sub under the merger agreement; or (b) settle, release, waive or compromise any legal proceeding, other than (i) routine collection or anti-piracy matters in the ordinary course of business and consistent with past practices, (ii) settlements providing solely for money damages payable by Ansys or its subsidiaries of less than $5 million and/or customary non-disparagement clauses or confidentiality provisions, involving no finding or admission of any wrongdoing on the part of Ansys or any of its subsidiaries or any of its or their officers, directors or employees (or current or future affiliates) and including a release of the claims at issue in such legal proceeding in form and substance reasonably satisfactory to Ansys and its subsidiaries or (iii) certain settlements entered into in accordance with merger agreement; |
• | waive, relinquish, abandon, forfeit, fail to renew, fail to continue to prosecute, protect or defend, permit to lapse, terminate or cancel any material intellectual property rights; |
• | (a) encumber, sell, transfer, convey title (in whole or in part) or otherwise dispose of (other than by licensing) any intellectual property rights in which any of Ansys or its subsidiaries has (or purports to have) an ownership interest (“Ansys IP”); or (b) license any material Ansys IP, other than granting non-exclusive licenses in the ordinary course of business consistent with past practice (i) to resellers and distributors (solely for their resale and distribution of Ansys products and the provision of support and services), (ii) to contractors, consultants or other service providers (solely for their provision of services to Ansys and its subsidiaries), (iii) to OEM customers or end users (solely to use Ansys IP in connection with the provision or sale to such OEM customers or end users of any Ansys products), (4) to OEM partners in connection with ensuring Ansys products are compatible with such partners’ hardware or are interoperable with such partners’ software or (5) pursuant to confidentiality or non-disclosure agreements solely for evaluation purposes; |
• | other than in the ordinary course of business, transfer or repatriate to the U.S. cash, cash equivalents or liquid short-term or long-term investments held outside the U.S. if any material U.S. withholding or income taxes would be incurred in connection with such transfer or repatriation; |
• | become party to or approve or adopt any stockholder rights plan or “poison pill” agreement or similar takeover protection; |
• | (a) maintain material insurance at less than current coverage levels or otherwise in a manner inconsistent with past practice; (b) engage in any transaction with, or enter into any agreement, arrangement or understanding with, any affiliate of Ansys or other person or entity covered by Item 404 of Regulation S K promulgated by the SEC that would be required to be disclosed pursuant to Item 404; or (C) effectuate a “plant closing” or “mass layoff” at any “single site of employment” (each as defined in the Worker Adjustment and Retraining Notification Act of 1988, as amended; or |
• | authorize, approve, agree, commit or offer to take any of the foregoing actions. |
• | declare, accrue, set aside, establish a record date for or pay any dividend or distribution (whether in cash, stock or otherwise) in respect of any shares of its capital stock or split, combine, subdivide or reclassify any of its capital stock; |
• | amend its certificate of incorporation or bylaws in a manner that would adversely affect Ansys or its stockholders in a manner disproportionate to Synopsys and its stockholders or in a manner that would adversely affect the ability of Synopsys or Merger Sub to complete the merger; |
• | adopt a plan of complete or partial liquidation, dissolution, bankruptcy restructuring or other similar reorganization; or |
• | permit any of its subsidiaries to, acquire any material business or assets of another person or entity, whether by merger, consolidation, purchase of property or assets (including equity interests) or otherwise, if the taking of such action would reasonably be expected (at the time such action is taken) to (a) prevent, materially delay or impede the completion of the merger or (b) cause any of the HSR waiting period condition, the foreign regulatory waiting period condition or the governmental authorization condition (each, as defined in the section “The Merger Agreement—Conditions to Completion of the Merger” beginning on page 114) to not be satisfied prior to the end date. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry (including by approving any transaction, or approving any person or entity (other than Synopsys and its affiliates) becoming an “interested stockholder” for purposes of Section 203 of the DGCL) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person or entity in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person or entity with respect to any acquisition proposal or acquisition inquiry (other than to inform such person or entity of the non-solicitation covenants in the merger agreement); |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction, other than an acceptable confidentiality agreement (as defined in “The Merger Agreement—No Solicitation by Ansys—Fiduciary Exception” beginning on page 101); or |
• | resolve or publicly propose to take any of the foregoing actions or do any of the foregoing. |
• | Ansys has not breached in any material respect (or be deemed to have breached in any material respect action by any action taken by any representative of Ansys or any of its subsidiaries) any of the no-shop covenants or board recommendation covenants; |
• | the Ansys board of directors determines in good faith, after having taken into account the advice of an independent financial advisor of nationally recognized reputation and Ansys’ outside legal counsel, that such acquisition proposal constitutes, or would reasonably be expected to lead to, a superior offer; |
• | the Ansys board of directors determines in good faith, after having taken into account the advice of Ansys’ outside legal counsel, that the failure to take such action would be inconsistent with the directors’ fiduciary obligations to Ansys stockholders under applicable Delaware law; |
• | at least 24 hours prior to furnishing any such non-public information to, or entering into discussions or negotiations with, such person or entity, Ansys (i) gives Synopsys written notice of the identity of such person or entity and of Ansys’ intention to furnish non-public information to, or enter into discussions or negotiations with, such person or entity (and its representatives) and (ii) receives from such person or entity, and delivers to Synopsys a copy of, an executed confidentiality agreement containing (a) customary limitations on the use and disclosure of all non-public information furnished to such person or entity by or on behalf of Ansys and (b) other provisions no less favorable in the aggregate to Ansys than the provisions of the confidentiality agreement as in effect immediately prior to the execution of the merger agreement; provided, that (x) for purposes of this clause “(b)” only, such confidentiality agreement need not contain a “standstill” or other provisions having a similar effect, (y) such confidentiality agreement will not prohibit compliance by Ansys with the no-shop covenants or board recommendation covenants; and (z) no new confidentiality agreement will be required if such person or entity and Ansys have a currently effective confidentiality agreement in place that satisfies the requirements of this clause “(b)”) (any such confidentiality agreement, an “acceptable confidentiality agreement”); and |
• | prior to or contemporaneously with furnishing any non-public information to such person or entity, Ansys furnishes such non-public information to Synopsys (to the extent such non-public information has not been previously furnished by Ansys to Synopsys). |
• | withdraw or modify in a manner adverse to Synopsys, or permit the withdrawal or the modification in a manner adverse to Synopsys of, the Ansys board recommendation; |
• | recommend the approval, acceptance or adoption of, or approve, endorse, accept or adopt, any acquisition proposal; |
• | approve or recommend, or cause or permit Ansys or any of its subsidiaries to execute or enter into, any letter of intent, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar document or contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction, other than acceptable confidentiality agreements (as defined in “The Merger Agreement—No Solicitation by Ansys—Fiduciary Exception” beginning on page 101); or resolve, agree or publicly propose, or permit Ansys or any of its subsidiaries, or any of its or their respective representatives, to agree or publicly propose, to take any of the actions contemplated in any of the preceding bullets (the actions set forth in the preceding bullets, collectively referred to as the “prohibited board actions”). |
• | the Ansys board of directors may withdraw or modify the Ansys board recommendation and/or cause Ansys to terminate the merger agreement if: (i) an unsolicited, bona fide, written acquisition proposal is made to Ansys after the date of the merger agreement and is not withdrawn; (ii) such acquisition proposal did not result from a breach of the no-shop covenants or board recommendation covenants in any material respect; (iii) the Ansys board of directors determines in good faith, after having taken into account the advice of an independent financial advisor of nationally recognized reputation and the advice of Ansys’ outside legal counsel, that such acquisition proposal constitutes a superior offer; (iv) the Ansys board of directors determines in good faith, after having taken into account the advice of Ansys’ outside legal counsel, that, in light of such superior offer, the failure to withdraw or modify the Ansys board recommendation or the failure to terminate the merger agreement pursuant to the fiduciary out termination right (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117) would be inconsistent with the directors’ fiduciary obligations to Ansys’ stockholders under applicable Delaware law; (v) no less than 120 hours prior to withdrawing or modifying the Ansys board recommendation, the Ansys board of directors delivers to Synopsys a written notice (a “recommendation change notice”) (a) stating that Ansys has received a superior offer that did not result from a breach of the no-shop covenants or board recommendation covenants in any material respect, (b) stating that the Ansys board of directors intends to withdraw or modify the Ansys board recommendation (and describing any intended modification of the Ansys board recommendation) and/or intends to terminate the merger agreement pursuant to the fiduciary out termination right in order to accept such superior offer, (c) specifying the material terms and conditions of such superior offer, including the identity of the person or entity making such superior offer and (d) attaching copies of the most current and complete draft of any Contract relating to such superior offer; (vi) for 120 hours after receipt by Synopsys of such recommendation change notice, the Ansys board of directors has not withdrawn or modified the Ansys board recommendation and Ansys has not attempted to terminate the merger agreement pursuant to the fiduciary out termination right; (vii) throughout such 120-hour period, Ansys engages (to the extent requested by Synopsys) in good faith negotiations with Synopsys to amend the merger agreement in such a manner that the failure to withdraw or modify the Ansys board recommendation or the failure to terminate the merger agreement pursuant to the fiduciary out termination right in order to accept such superior offer would not be inconsistent with the directors’ fiduciary obligations to Ansys’ stockholders under applicable Delaware law; and (viii) at the time of withdrawal or modification of the Ansys board recommendation, the Ansys board of directors determines in good faith, after taking into account the advice of an independent financial advisor of nationally recognized reputation and the advice of Ansys’ outside legal counsel, that the failure to withdraw or modify the Ansys board recommendation or the failure to terminate the merger agreement pursuant to the fiduciary out termination right in order to accept such superior offer would be inconsistent with the fiduciary obligations of the Ansys board of directors to the Ansys stockholders under applicable Delaware law in light of such superior offer; provided, however, that when making such determination, the Ansys board of directors will be obligated to consider any changes to the terms of the merger agreement proposed by Synopsys as a result of the negotiations required by clause “(vii)” above or otherwise; |
• | the Ansys board of directors may withdraw or modify the Ansys board recommendation if: (i) there arises after the date of the merger agreement an event, development or change in circumstances that relates to and is material to Ansys or its subsidiaries, taken as a whole (but does not relate to (x) any acquisition proposal or (y) changes in the stock price or trading volume of Synopsys common stock or any other securities of Synopsys or any of its subsidiaries, any change in credit rating of Synopsys or any of its subsidiaries or the failure of Synopsys to meet internal or securities analysts’ published projections of earnings or revenues) and that was not known and was not reasonably foreseeable by the Ansys board of directors on the date of the merger agreement (or if known, the material consequences of which were not known, and were not reasonably foreseeable by the Ansys board of directors as of |
• | (i) within 10 business days after the date of the merger agreement, make an appropriate filing of a notification and report form pursuant to the HSR Act, (ii) prepare, file and submit the notifications, reports and other documents (or, if appropriate, drafts of documents) required under any applicable foreign antitrust or competition laws or regulations in the specified antitrust jurisdictions as soon as reasonably practicable and advisable and (iii) promptly after the date of the merger agreement, prepare, file and submit the notifications, reports and other documents required under (a) any applicable foreign investment laws in the specified foreign investment jurisdictions and (b) 32 CFR Part 117 (the |
• | respond as promptly as practicable to (i) any inquiries or requests received from the FTC or the DOJ for additional information or documentation and (ii) any inquiries or requests received from any state attorney general, foreign antitrust authority or other governmental body in connection with antitrust, foreign direct investment, security clearance or related matters; and |
• | except to the extent Synopsys determines otherwise: (i) promptly (and in any event within 10 business days) after a non-U.S. governmental body (referred to as a “requesting authority”) asserts or attempts to assert jurisdiction over, or requests, requires or attempts to require a filing or submission relating to, the merger or any of the other transactions contemplated by the merger agreement, consult with one another in good faith to determine whether such filing is required and, if Synopsys determines such filing is required to complete the merger or any of the other transactions contemplated by the merger agreement, file and submit (in accordance with each legal requirement that may be applicable or that such requesting authority asserts to be applicable) all notices, reports and other documents required or requested by such requesting authority to be filed or submitted, in each case, promptly after Synopsys makes such determination, and (ii) respond as promptly as practicable to any inquiries or requests received from such requesting authority for additional information or documentation. |
• | consult with the other party in good faith prior to taking a position with respect to any filing or submission required by the regulatory efforts covenants; |
• | provide the other party a reasonable opportunity to review, comment and discuss in advance, and consider in good faith the views of the other party in connection with, all written, substantive communications with a governmental body (including any requesting authority) in connection with any filing or submission required by the regulatory efforts covenants (including any analyses, appearances, presentations, memoranda, briefs, white papers, arguments, opinions or proposals) before making or submitting any such written communication to any governmental body on behalf of any party hereto in connection with any filing or submission required by the regulatory efforts covenants or any legal proceeding involving a governmental body with regulatory authority related to the merger agreement or any of the transactions contemplated by the merger agreement; |
• | coordinate with the other party in preparing and exchanging such information; and |
• | promptly provide the other party (and its counsel) with copies of all filings, notices, analyses, presentations, memoranda, briefs, white papers, opinions, proposals and other submissions (and a summary of any oral presentations) made or submitted by such party with or to any governmental body in connection with any required filing or submission (subject to certain redactions permitted under the merger agreement). |
• | the Form S-4 registration statement of which this proxy statement/prospectus is a part has become effective in accordance with the provisions of the Securities Act, no stop order suspending its effectiveness has been issued by the SEC and remains in effect and no proceedings for that purpose have been initiated or threatened in writing by the SEC that have not been withdrawn; |
• | the shares of Synopsys common stock to be issued in the merger have been approved for listing (subject to official notice of issuance) on the NASDAQ; |
• | the merger agreement has been duly adopted at the special meeting by the required Ansys stockholder vote (such condition referred to as the “stockholder approval condition”); |
• | the waiting period (and any extension thereof) applicable to the completion of the merger under the HSR Act has expired or been terminated, and any period of time (and any extension thereof) agreed to with a governmental body in the United States not to complete the merger has expired or been terminated (such condition referred to as the “HSR waiting period condition”); |
• | any waiting period (and any extension thereof) applicable to the completion of the merger under applicable foreign antitrust law or regulation of the specified jurisdictions has expired or otherwise been terminated, and any period of time (and any extension thereof) agreed to with a governmental body in any specified jurisdiction not to complete the merger has expired or been terminated (such condition referred to as the “foreign regulatory waiting period condition”); |
• | any governmental authorization or other consent required under applicable foreign antitrust law or regulation or foreign investment law in connection with the merger in each specified jurisdiction has been obtained and is in full force and effect (such condition referred to as the “governmental authorization condition”); and |
• | no temporary restraining order, preliminary or permanent injunction or other order preventing the completion of the merger has been issued by any governmental body in the United States or any of the specified jurisdictions and remains in effect, and there has not been any legal requirement enacted or deemed applicable to the merger by any governmental body in any specified jurisdiction that makes completion of the merger illegal (such condition referred to as the “no restraint condition”). |
• | the representations and warranties made by Ansys in the merger agreement relating to the authorization and validity of the merger agreement, takeover statutes and stockholder rights plans, the required Ansys stockholder vote, non-contravention with Ansys’ organizational documents, the opinions of Ansys’ financial advisors and advisors’ fees were accurate in all material respects as of the date of the merger agreement and will be accurate in all material respects as of the closing date as if made on and as of the closing date (in each case, other than any such representation or warranty made as of a specific earlier date, which must have been accurate in all material respects as of such earlier date); provided, however, that for purposes of determining the accuracy of such representations and warranties as of the foregoing dates, all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations and warranties (other than dollar thresholds) will be disregarded, and any update of or modification to Ansys disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded; |
• | the representations and warranties made by Ansys in the merger agreement relating to certain capitalization and related matters were accurate in all respects as of the date of the merger agreement |
• | the representation and warranty made by Ansys in the merger agreement regarding the absence of any material adverse effect on Ansys between September 30, 2023 and the date of the merger agreement was accurate in all respects as of the date of the merger agreement; provided, however, that for purposes of determining the accuracy of such representation and warranty as of the foregoing date, any update of or modification to Ansys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded; |
• | all other representations and warranties made by Ansys in the merger agreement were accurate in all respects as of the date of the merger agreement and will be accurate in all respects as of the closing date as if made on and as of the closing date (other than any such representation or warranty made as of a specific earlier date, which must have been accurate in all respects as of such earlier date), except to the extent that any inaccuracies in such representations and warranties (at any such time) do not have, and would not reasonably be expected to have, a material adverse effect on Ansys; provided, however, that for purposes of determining the accuracy of such representations and warranties as of the foregoing dates, all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations and warranties (other than dollar thresholds) will be disregarded, and any update of or modification to Ansys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded; |
• | the covenants and obligations in the merger agreement that Ansys is required to comply with or to perform at or prior to the completion of the merger have been complied with and performed in all material respects; |
• | receipt by Synopsys of a certificate executed by Ansys’ Chief Executive Officer and Chief Financial Officer confirming that the closing conditions relating to Ansys’ representations and warranties and compliance with covenants have been duly satisfied; and |
• | since the date of the merger agreement, there has not occurred any material adverse effect on Ansys that is continuing. |
• | the representations and warranties made by Synopsys in the merger agreement relating to the authorization and validity of the merger agreement and the absence of ownership of Ansys capital stock and related matters were accurate in all material respects as of the date of the merger agreement and will be accurate in all material respects as of the closing date as if made on and as of the closing date (other than any such representation or warranty made as of a specific earlier date, which must have been accurate in all respects as of such earlier date); provided, however, that for purposes of determining the accuracy of such representations and warranties as of the foregoing dates, all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations and warranties (other than dollar thresholds) will be disregarded, and any update of or modification to Synopsys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded; |
• | the representations and warranties made by Synopsys in the merger agreement relating to certain capitalization and related matters were accurate in all respects as of the date of the merger agreement and will be accurate in all respects as of the closing date as if made on and as of the closing date (in each case, other than any representation or warranty made as of a specific earlier date, which must have been accurate in all respects as of such earlier date), except that any inaccuracies in such representations and warranties that are, in the aggregate, de minimis will be disregarded; provided, |
• | the representation and warranty made by Synopsys in the merger agreement regarding the absence of any material adverse effect on Synopsys between October 28, 2023 and the date of the merger agreement was accurate in all respects as of the date of the merger agreement; |
• | all other representations and warranties made by Synopsys in the merger agreement were accurate in all respects as of the date of the merger agreement and will be accurate in all respects as of the closing date as if made on and as of the closing date (other than any such representation or warranty made as of a specific earlier date, which must have been accurate in all respects as of such earlier date), except to the extent that any inaccuracies in such representations and warranties (at any such time) do not have, and would not reasonably be expected to have, a material adverse effect on Synopsys; provided, however, that for purposes of determining the accuracy of such representations and warranties as of the foregoing dates, all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations and warranties (other than dollar thresholds) will be disregarded, and any update of or modification to Synopsys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded; |
• | the covenants and obligations in the merger agreement that Synopsys and Merger Sub are required to comply with or to perform at or prior to the closing have been complied with and performed in all material respects; |
• | receipt by Ansys of a certificate executed on behalf of Synopsys by an officer of Synopsys confirming that the conditions relating to Synopsys’ representations and warranties and compliance with covenants have been duly satisfied; and |
• | since the date of the merger agreement, there has not occurred any material adverse effect on Synopsys that is continuing. |
• | by the mutual written consent of Synopsys and Ansys; |
• | by either Synopsys and Ansys if the merger has not been completed by 11:59 p.m. (California time) on January 15, 2025; provided, however, that: (i) if, at 11:59 p.m. (California time) on January 15, 2025, any of the regulatory approval conditions has not been satisfied or waived, then the end date will be automatically extended, without any further action on the part of Synopsys or Ansys, to July 15, 2025; (ii) if, on July 15, 2025, any of the regulatory approval conditions has not been satisfied or waived, then either Synopsys or Ansys may, by providing written notice thereof to the other party at or prior to 11:59 p.m. (California time) on July 15, 2025, extend the end date to January 15, 2026; and (iii) neither Synopsys nor Ansys is permitted to terminate the merger agreement on such basis if the failure to complete the merger by the end date is primarily attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time in breach of such party’s obligations; |
• | by either Synopsys or Ansys if: (i) a governmental body in any specified jurisdiction has issued a final and nonappealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger; or (ii) there has been any applicable legal requirement enacted, enforced or deemed applicable to the merger by any governmental body in any specified jurisdiction that would make completion of the merger illegal; |
• | by either Synopsys or Ansys if: (i) the special meeting (including any adjournments and postponements thereof) has been held and completed and the Ansys stockholders have taken a final vote on a proposal |
• | by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event (as defined below) has occurred; |
• | by Synopsys if: (i) any of Ansys’ representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement or have become inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that any of the closing conditions relating to the accuracy of Ansys’ representations and warranties would not be satisfied (and for purposes of determining the accuracy of such representations or warranties as of the date of the merger agreement or as of any subsequent date, (a) all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations or warranties (other than dollar thresholds) will be disregarded, and (b) any update of or modification to Ansys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded); or (ii) any of Ansys’ covenants or obligations contained in the merger agreement have been breached such that any of the closing conditions relating to the performance by Ansys of its covenants would not be satisfied; provided, however, that: (a) if an inaccuracy in any of Ansys’ representations or warranties as of a date subsequent to the date of the merger agreement or a breach of a covenant or obligation by Ansys is curable by Ansys prior to the end date, and Ansys is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Synopsys may not terminate the merger agreement on account of such inaccuracy or breach unless such inaccuracy or breach has not been cured by Ansys on or prior to the earlier of (x) the business day immediately prior to the end date and (y) 30 days after the date on which Synopsys gives Ansys written notice of such inaccuracy or breach; and (b) Synopsys is not permitted to terminate the merger agreement pursuant to termination right if Synopsys is then in breach of any of its representations, warranties, covenants or obligations contained in the merger agreement, which breach would give rise to the failure of any of the closing conditions relating to the accuracy of Synopsys’ representations and warranties or the performance by Synopsys of its covenants to be satisfied; |
• | by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into a definitive agreement providing for the completion of the transaction contemplated by such superior offer that has been executed on behalf of the person or entity that made such superior offer (an “alternative acquisition agreement”), only if: (i) Ansys has complied with the no-shop covenants in all material respects; (ii) the Ansys board of directors, after satisfying after satisfying the requirements under the board recommendation covenants, have authorized Ansys to enter into such alternative acquisition agreement; (iii) Ansys has delivered to Synopsys a written notice (that includes a copy of the alternative acquisition agreement as an attachment) confirming that Ansys will enter into the alternative acquisition agreement in the form attached to such notice concurrently with the termination of the merger agreement; (iv) concurrently with the termination of the merger agreement, Ansys enters into the alternative acquisition agreement with respect to such superior offer; and (v) immediately prior to or concurrently with such termination, Ansys has paid to Synopsys or its designee the termination fee (as defined below) (such termination right referred to herein as the “fiduciary out termination right”); or |
• | by Ansys if: (i) any of Synopsys’ representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement, or have become inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that the closing condition relating to the accuracy of Synopsys’ representations and warranties would not be satisfied (and for purposes of determining the accuracy of such representations or warranties as of the date of the merger agreement or as of any subsequent date, (a) all “material adverse effect” and other materiality and similar qualifications limiting the scope of such representations or warranties (other than dollar thresholds) will be disregarded, and (b) any update of or modification to Synopsys’ disclosure schedule made or purported to have been made after the execution and delivery of the merger agreement will be disregarded); or (i) if any of Synopsys’ covenants or obligations contained in the merger agreement have been breached such that the closing condition relating to the performance |
• | (i) by Synopsys or Ansys because the merger has not been completed by 11:59 p.m. (California time) on the end date (prior to the satisfaction of stockholder approval condition) or upon the occurrence of the no stockholder approval event; (ii) at or prior to the time of the termination of the merger agreement, but on or after the date of the merger agreement, an acquisition proposal has been publicly disclosed, announced, commenced, submitted or made and such acquisition proposal has not been publicly withdrawn at least 10 calendar days prior to the special meeting (or, in the case of a termination because the merger has not been completed by 11:59 p.m. (California time) on the end date, an acquisition proposal otherwise exists and has not been withdrawn); and (iii) within 12 months after the date of termination of the merger agreement, an acquisition transaction (whether or not relating to such acquisition proposal) is completed or a definitive agreement providing for an acquisition transaction (whether or not related to such acquisition proposal) is executed; provided, however, that, for purposes of clause (iii) above, all references to “15%” and “85%” in the definition of “acquisition transaction” will be deemed to be references to “50%”; or |
• | (i) by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event has occurred; (ii) by Synopsys or Ansys because the special meeting has been held and completed but the merger agreement has not been adopted by the required Ansys stockholder vote at the special meeting or at any adjournment or postponement thereof; or (iii) by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into an alternative acquisition agreement. |
• | as a result of a regulatory proceeding brought by a governmental body under any applicable antitrust or competition legal requirement or any applicable foreign investment law in any specified jurisdiction; or |
• | by Synopsys or Ansys because the merger has not been completed by 11:59 p.m. (California time) on the end date and, at the time of termination, all the closing conditions set forth in the merger agreement (other than those conditions that by their terms are to be satisfied at the closing) have been satisfied or waived, other than the regulatory approval conditions (solely in connection with any applicable antitrust law or regulation or foreign investment law in the specified jurisdictions). |
(a) | $197.00 per share in cash, without interest, and |
(b) | 0.3450 shares of Synopsys common stock, $0.01 par value per share, plus cash in lieu of any fractional shares. |
• | the accompanying notes to the unaudited pro forma condensed combined financial information; |
• | the separate historical audited consolidated financial statements of Synopsys as of and for the year ended October 28, 2023, included in Synopsys’ Annual Report on Form 10-K filed with the SEC on December 12, 2023, and incorporated by reference in this proxy statement/prospectus; |
• | the separate historical unaudited condensed consolidated financial statements of Synopsys as of and for the three months ended February 3, 2024, included in Synopsys’ Quarterly Report on Form 10-Q filed with the SEC on February 23, 2024, and incorporated by reference in this proxy statement/prospectus; |
• | the separate historical audited consolidated financial statements of Ansys as of December 31, 2023, included in Ansys’ Annual Report on Form 10-K filed with the SEC on February 21, 2024, and incorporated by reference in this proxy statement/prospectus; |
• | the separate historical unaudited condensed consolidated financial statements of Ansys as of and for the nine months ended September 30, 2023, included in Ansys’ Quarterly Report on Form 10-Q filed with the SEC on November 1, 2023, and incorporated by reference in this proxy statement/prospectus; and |
• | the separate historical unaudited condensed consolidated financial statements of Ansys as of and for the nine months ended September 30, 2022, included in Ansys’ Quarterly Report on Form 10-Q filed with the SEC on November 2, 2022, and incorporated by reference in this proxy statement/prospectus. |
| | As of January 31, 2024 | | | As of December 31, 2023 | | | | | | | | | | | | | | | ||||||||
| | SYNOPSYS, INC. (Historical) | | | ANSYS, INC. (Historical) | | | Reclassification Adjustments | | | | | Transaction accounting adjustments | | | | | Financing Adjustments | | | | | Pro Forma Combined | ||||
ASSETS | | | | | | | | | | | | | | | | | | | |||||||||
Current assets | | | | | | | | | | | | | | | | | | | |||||||||
Cash and cash equivalents | | | 1,118,944 | | | 860,201 | | | — | | | | | (17,929,451) | | | 5a | | | 16,474,665 | | | 7a | | | 150,663 | |
| | | | | | — | | | | | (185,300) | | | 5b | | | — | | | | | ||||||
| | | | | | — | | | | | (156,290) | | | 5c | | | — | | | | | ||||||
| | | | | | — | | | | | (23,106) | | | 5l | | | — | | | | | ||||||
| | | | | | — | | | | | (9,000) | | | 5d | | | — | | | | | ||||||
Short-term investments | | | 154,490 | | | 189 | | | — | | | | | — | | | | | — | | | | | 154,679 | |||
Accounts receivable, net | | | 1,064,135 | | | 864,526 | | | 253,646 | | | 3a | | | (13,995) | | | 5g | | | — | | | | | 2,400,395 | |
| | | | | | 232,083 | | | 3f | | | — | | | | | — | | | | | ||||||
Inventories | | | 382,727 | | | — | | | — | | | | | — | | | | | — | | | | | 382,727 | |||
Prepaid and other current assets | | | 687,632 | | | — | | | 71,005 | | | 3e | | | (25) | | | 5g | | | — | | | | | 758,379 | |
| | | | | | (233) | | | 3f | | | — | | | | | — | | | | | ||||||
Other receivables and current assets | | | — | | | 324,651 | | | (253,646) | | | 3a | | | — | | | | | — | | | | | — | ||
| | | | | | (71,005) | | | 3e | | | — | | | | | — | | | | | ||||||
Total current assets | | | 3,407,928 | | | 2,049,567 | | | 231,850 | | | | | (18,317,167) | | | | | 16,474,665 | | | | | 3,846,843 | |||
Property and equipment, net | | | 567,038 | | | 77,780 | | | — | | | | | 17,104 | | | 5e | | | — | | | | | 661,922 | ||
Operating lease right-of-use assets, net | | | 551,452 | | | 116,980 | | | — | | | | | (6,560) | | | 5n | | | — | | | | | 661,872 | ||
Goodwill | | | 4,131,418 | | | 3,805,874 | | | — | | | | | (3,805,874) | | | 5k | | | — | | | | | 27,942,156 | ||
| | | | | | — | | | | | 23,810,738 | | | 5f | | | — | | | | | ||||||
Intangible assets, net | | | 377,415 | | | 835,417 | | | — | | | | | 12,004,583 | | | 5h | | | — | | | | | 13,217,415 | ||
Deferred income taxes | | | 954,495 | | | 164,227 | | | — | | | | | — | | | | | — | | | | | 1,118,722 | |||
Other long-term assets | | | 568,513 | | | 273,030 | | | — | | | | | (52,328) | | | 5g | | | — | | | | | 789,215 | ||
Total assets | | | 10,558,259 | | | 7,322,875 | | | 231,850 | | | | | 13,650,496 | | | | | 16,474,665 | | | | | 48,238,145 | |||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | | | | | | | | | | | | | | | | | | | |||||||||
Current liabilities | | | | | | | | | | | | | | | | | | | |||||||||
Accounts payable and accrued liabilities | | | 699,474 | | | — | | | 408,474 | | | 3b | | | (528) | | | 5j | | | — | | | | | 1,108,040 | |
| | | | | | 1,700 | | | 3f | | | (1,080) | | | 5g | | | — | | | | | |||||
Accounts payable | | | — | | | 22,772 | | | (22,772) | | | 3b | | | — | | | | | — | | | | | — | ||
Accrued bonuses and commissions | | | — | | | 170,909 | | | (170,909) | | | 3b | | | — | | | | | — | | | | | — | ||
Accrued income taxes | | | — | | | 22,454 | | | (22,454) | | | 3b | | | — | | | | | — | | | | | — | ||
Other accrued expenses and liabilities | | | — | | | 215,645 | | | (192,339) | | | 3b | | | — | | | | | — | | | | | — | ||
| | | | | | (23,306) | | | 3c | | | — | | | | | — | | | | | ||||||
Operating lease liabilities | | | 89,194 | | | — | | | 23,306 | | | 3c | | | — | | | | | — | | | | | 112,500 | ||
Deferred revenue | | | 1,855,839 | | | 457,514 | | | 175,231 | | | 3f | | | (486) | | | 5g | | | — | | | | | 2,488,098 | |
Current portion of long-term debt | | | — | | | — | | | — | | | | | — | | | | | 11,330,250 | | | 7a | | | 11,330,250 | ||
Total current liabilities | | | 2,644,507 | | | 889,294 | | | 176,931 | | | | | (2,094) | | | | | 11,330,250 | | | | | 15,038,888 | |||
Deferred income taxes | | | — | | | 75,301 | | | — | | | | | 2,800,753 | | | 5m | | | — | | | | | 2,876,054 | ||
Long-term operating lease liabilities | | | 563,815 | | | 100,505 | | | — | | | | | — | | | | | — | | | | | 664,320 | |||
Long-term deferred revenue | | | 189,841 | | | — | | | 22,240 | | | 3d | | | — | | | | | — | | | | | 267,000 | ||
| | | | | | 54,919 | | | 3f | | | — | | | | | — | | | | | ||||||
Long-term debt | | | 16,951 | | | 753,891 | | | — | | | | | 1,109 | | | 5i | | | 5,144,415 | | | 7a | | | 5,161,366 | |
| | — | | | | | — | | | | | (755,000) | | | 5j | | | — | | | | | |||||
Other long-term liabilities | | | 436,528 | | | 113,520 | | | (22,240) | | | 3d | | | — | | | | | — | | | | | 527,808 | ||
Total liabilities | | | 3,851,642 | | | 1,932,511 | | | 231,850 | | | | | 2,044,768 | | | | | 16,474,665 | | | | | 24,535,436 | |||
Redeemable non-controlling interest | | | 31,043 | | | — | | | — | | | | | — | | | | | — | | | | | 31,043 | |||
Stockholders' equity | | | | | | | | | | | | | | | | | | | |||||||||
Preferred stock, $ 0.01 par value | | | — | | | — | | | — | | | | | — | | | | | — | | | | | — | |||
Common stock, $ 0.01 par value | | | 1,525 | | | 953 | | | — | | | | | 301 | | | 5a | | | — | | | | | 1,826 | ||
| | | | | | — | | | | | (953) | | | 5k | | | — | | | | | ||||||
Capital in excess of par value | | | 1,183,473 | | | 1,670,450 | | | — | | | | | 17,213,197 | | | 5a | | | — | | | | | 18,419,543 | ||
| | | | | | — | | | | | (1,670,450) | | | 5k | | | — | | | | | ||||||
| | | | | | — | | | | | 22,873 | | | 5l | | | — | | | | | ||||||
Retained earnings | | | 7,188,550 | | | 5,283,342 | | | — | | | | | (185,300) | | | 5b | | | — | | | | | 6,948,271 | ||
| | | | | | — | | | | | (5,283,342) | | | 5k | | | — | | | | | ||||||
| | | | | | — | | | | | (45,979) | | | 5l | | | — | | | | | ||||||
| | | | | | — | | | | | (9,000) | | | 5d | | | — | | | | | ||||||
Treasury stock, at cost | | | (1,539,340) | | | (1,474,110) | | | — | | | | | 1,474,110 | | | 5k | | | — | | | | | (1,539,340) | ||
Accumulated other comprehensive income (loss) | | | (163,224) | | | (90,271) | | | — | | | | | 90,271 | | | 5k | | | — | | | | | (163,224) | ||
Total stockholders' equity | | | 6,670,984 | | | 5,390,364 | | | — | | | | | 11,605,728 | | | | | — | | | | | 23,667,076 | |||
Non-controlling interest | | | 4,590 | | | — | | | — | | | | | — | | | | | — | | | | | 4,590 | |||
Total liabilities, redeemable non-controlling interest and stockholders’ equity | | | 10,558,259 | | | 7,322,875 | | | 231,850 | | | | | 13,650,496 | | | | | 16,474,665 | | | | | 48,238,145 |
| | For the three months ended January 31, 2024 | | | | | For the three months ended December 31, 2023 | | | | | | | | | | | | | | | | | ||||||||||
| | SYNOPSYS, INC. (Historical) | | | | | ANSYS, INC. (Historical) | | | Reclassification Adjustments | | | | | Transaction accounting adjustments | | | | | Financing Adjustments | | | | | Pro Forma Combined | | | ||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Time-based products | | | 904,378 | | | | | — | | | — | | | | | — | | | | | — | | | | | 904,378 | | | |||||
Upfront products | | | 447,863 | | | | | — | | | 502,277 | | | 3g | | | (44,170) | | | 6h | | | — | | | | | 905,970 | | | |||
Software licenses | | | — | | | | | 502,277 | | | (502,277) | | | 3g | | | — | | | | | — | | | | | — | | | ||||
Maintenance and service | | | 296,989 | | | | | 302,831 | | | — | | | | | (1,502) | | | 6h | | | — | | | | | 598,318 | | | ||||
Total Revenue: | | | 1,649,230 | | | | | 805,108 | | | — | | | | | (45,672) | | | | | — | | | | | 2,408,666 | | | |||||
Costs of revenue: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Products | | | 193,638 | | | | | — | | | 10,909 | | | 3h | | | (6) | | | 6b | | | — | | | | | 204,541 | | | |||
Software licenses | | | — | | | | | 10,909 | | | (10,909) | | | 3h | | | — | | | | | — | | | | | — | | | ||||
Maintenance and service | | | 115,081 | | | | | 38,554 | | | — | | | | | (226) | | | 6b | | | — | | | | | 153,961 | | | ||||
| | | | | | | | — | | | | | 577 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (25) | | | 6f | | | — | | | | | | | ||||||||
Amortization of intangible asset | | | 20,456 | | | | | 20,586 | | | — | | | | | 211,557 | | | 6a | | | — | | | | | 252,599 | | | ||||
Total Costs of revenue: | | | 329,175 | | | | | 70,049 | | | — | | | | | 211,877 | | | | | — | | | | | 611,101 | | | |||||
Gross margin | | | 1,320,055 | | | | | 735,059 | | | — | | | | | (257,549) | | | | | — | | | | | 1,797,565 | | | |||||
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Research and development | | | 552,056 | | | | | 126,288 | | | — | | | | | (871) | | | 6b | | | — | | | | | 680,921 | | | ||||
| | | | | | | | — | | | | | 3,539 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (91) | | | 6f | | | — | | | | | | | ||||||||
Sales and marketing | | | 263,408 | | | | | — | | | 213,056 | | | 3i | | | (753) | | | 6b | | | — | | | | | 479,522 | | | |||
| | | | | | | | — | | | | | 3,910 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (99) | | | 6f | | | — | | | | | | | ||||||||
General and administrative | | | 138,374 | | | | | — | | | 56,801 | | | 3i | | | (341) | | | 6b | | | — | | | | | 195,098 | | | |||
| | | | | | | | — | | | | | 1,377 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (1,080) | | | 6h | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (33) | | | 6f | | | — | | | | | | | ||||||||
Selling, general and administrative | | | — | | | | | 269,857 | | | (269,857) | | | 3i | | | — | | | | | — | | | | | — | | | ||||
Amortization of intangible assets | | | 6,597 | | | | | 5,914 | | | — | | | | | 150,701 | | | 6a | | | — | | | | | 163,212 | | | ||||
Restructuring charges | | | — | | | | | — | | | — | | | | | — | | | | | — | | | | | — | | | |||||
Total Operating expenses: | | | 960,435 | | | | | 402,059 | | | — | | | | | 156,259 | | | | | — | | | | | 1,518,753 | | | |||||
Operating income | | | 359,620 | | | | | 333,000 | | | — | | | | | (413,808) | | | | | — | | | | | 278,812 | | | |||||
Interest income | | | — | | | | | 7,199 | | | (7,199) | | | 3j | | | — | | | | | — | | | | | — | | | ||||
Interest expense | | | — | | | | | (12,551) | | | 12,551 | | | 3j | | | — | | | | | — | | | | | — | | | ||||
Other income (expense), net | | | 105,484 | | | | | (2,876) | | | (5,352) | | | 3j | | | 12,535 | | | 6d | | | (273,338) | | | 7b | | | (181,222) | | | ||
| | | | | | | | — | | | | | — | | | | | (17,675) | | | 7c | | | | | ||||||||
Income before income taxes | | | 465,104 | | | | | 324,772 | | | — | | | | | (401,273) | | | | | (291,013) | | | | | 97,590 | | | |||||
Provision (benefit) for income taxes | | | 18,897 | | | | | 50,010 | | | — | | | | | (84,267) | | | 6e | | | (61,113) | | | 6e | | | (76,473) | | | |||
Net income | | | 446,207 | | | | | 274,762 | | | — | | | | | (317,006) | | | | | (229,900) | | | | | 174,063 | | | |||||
Net income (loss) attributed to non-controlling interest and redeemable non-controlling interest | | | (2,905) | | | | | — | | | — | | | | | — | | | | | — | | | | | (2,905) | | | |||||
Net income attributed to Synopsys | | | 449,112 | | | | | 274,762 | | | — | | | | | (317,006) | | | | | (229,900) | | | | | 176,968 | | | |||||
Net income per share attributed to Synopsys: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Basic | | | $2.95 | | | | | — | | | — | | | | | — | | | | | — | | | | | $0.97 | | | 6j | ||||
Diluted | | | $2.89 | | | | | — | | | — | | | | | — | | | | | — | | | | | $0.95 | | | 6j | ||||
Shares used in computing per share amounts: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Basic | | | 152,311 | | | | | — | | | — | | | | | — | | | | | — | | | | | 182,389 | | | |||||
Diluted | | | 155,334 | | | | | — | | | — | | | | | — | | | | | — | | | | | 186,334 | | |
| | For the year ended October 31, 2023 | | | | | For the twelve months ended September 30, 2023 | | | | | | | | | | | | | | | | | ||||||||||
| | SYNOPSYS, INC. (Historical) | | | | | ANSYS, INC. (Historical) | | | Reclassification Adjustments | | | | | Transaction accounting adjustments | | | | | Financing Adjustments | | | | | Pro Forma Combined | | | ||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Time-based products | | | 3,383,632 | | | | | — | | | — | | | | | — | | | | | — | | | | | 3,383,632 | | | |||||
Upfront products | | | 1,429,330 | | | | | — | | | 1,000,117 | | | 3g | | | (270) | | | 6h | | | — | | | | | 2,429,177 | | | |||
Software licenses | | | — | | | | | 1,000,117 | | | (1,000,117) | | | 3g | | | — | | | | | — | | | | | — | | | ||||
Maintenance and service | | | 1,029,657 | | | | | 1,158,839 | | | — | | | | | (2,916) | | | 6h | | | — | | | | | 2,185,580 | | | ||||
Total Revenue: | | | 5,842,619 | | | | | 2,158,956 | | | — | | | | | (3,186) | | | | | — | | | | | 7,998,389 | | | |||||
Costs of revenue: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Products | | | 763,494 | | | | | — | | | 36,806 | | | 3h | | | (26) | | | 6b | | | — | | | | | 800,274 | | | |||
Software licenses | | | — | | | | | 36,806 | | | (36,806) | | | 3h | | | — | | | | | — | | | | | — | | | ||||
Maintenance and service | | | 383,835 | | | | | 148,041 | | | — | | | | | (1,044) | | | 6b | | | — | | | | | 537,719 | | | ||||
| | | | | | | | — | | | | | 6,991 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (104) | | | 6f | | | — | | | | | | | ||||||||
Amortization of intangible asset | | | 74,864 | | | | | 77,829 | | | — | | | | | 850,742 | | | 6a | | | — | | | | | 1,003,435 | | | ||||
Total Costs of revenue: | | | 1,222,193 | | | | | 262,676 | | | — | | | | | 856,559 | | | | | — | | | | | 2,341,428 | | | |||||
Gross margin | | | 4,620,426 | | | | | 1,896,280 | | | — | | | | | (859,745) | | | | | — | | | | | 5,656,961 | | | |||||
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Research and development | | | 1,946,813 | | | | | 479,971 | | | — | | | | | (3,890) | | | 6b | | | — | | | | | 2,467,086 | | | ||||
| | | | | | | | — | | | | | 44,552 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (360) | | | 6f | | | — | | | | | | | ||||||||
Sales and marketing | | | 889,016 | | | | | — | | | 632,172 | | | 3i | | | (3,492) | | | 6b | | | — | | | | | 1,570,804 | | | |||
| | | | | | | | — | | | | | 53,507 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (399) | | | 6f | | | — | | | | | | | ||||||||
General and administrative | | | 410,311 | | | | | — | | | 210,556 | | | 3i | | | 195,300 | | | 6g | | | — | | | | | 837,831 | | | |||
| | | | | | | | — | | | | | 9,000 | | | 6i | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (1,546) | | | 6b | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | 17,529 | | | 6c | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (3,186) | | | 6h | | | — | | | | | | | ||||||||
| | | | | | | | — | | | | | (133) | | | 6f | | | — | | | | | | | ||||||||
Selling, general and administrative | | | — | | | | | 842,728 | | | (842,728) | | | 3i | | | — | | | | | — | | | | | — | | | ||||
Amortization of intangible assets | | | 28,025 | | | | | 20,345 | | | — | | | | | 606,117 | | | 6a | | | — | | | | | 654,487 | | | ||||
Restructuring charges | | | 77,002 | | | | | — | | | — | | | | | — | | | | | — | | | | | 77,002 | | | |||||
Total Operating expenses: | | | 3,351,167 | | | | | 1,343,044 | | | — | | | | | 912,999 | | | | | — | | | | | 5,607,210 | | | |||||
Operating income | | | 1,269,259 | | | | | 553,236 | | | — | | | | | (1,772,744) | | | | | — | | | | | 49,751 | | | |||||
Interest income | | | — | | | | | 15,965 | | | (15,965) | | | 3j | | | — | | | | | — | | | | | — | | | ||||
| | — | | | | | (43,652) | | | 43,652 | | | 3j | | | — | | | | | — | | | | | — | | | |||||
Other income (expense), net | | | 32,523 | | | | | (1,772) | | | (27,687) | | | 3j | | | 43,561 | | | 6d | | | (1,092,683) | | | 7b | | | (1,091,555) | | | ||
| | | | | | | | — | | | | | — | | | | | (45,497) | | | 7c | | | | | ||||||||
Income before income taxes | | | 1,301,782 | | | | | 523,777 | | | — | | | | | (1,729,183) | | | | | (1,138,180) | | | | | (1,041,804) | | | |||||
Provision (benefit) for income taxes | | | 83,657 | | | | | 40,180 | | | — | | | | | (340,829) | | | 6e | | | (239,018) | | | 6e | | | (456,010) | | | |||
Net income | | | 1,218,125 | | | | | 483,597 | | | — | | | | | (1,388,354) | | | | | (899,162) | | | | | (585,794) | | | |||||
Net income (loss) attributed to non-controlling interest and redeemable non-controlling interest | | | (11,763) | | | | | — | | | — | | | | | — | | | | | — | | | | | (11,763) | | | |||||
Net income attributed to Synopsys | | | 1,229,888 | | | | | 483,597 | | | — | | | | | (1,388,354) | | | | | (899,162) | | | | | (574,031) | | | |||||
Net income per share attributed to Synopsys: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Basic | | | $8.08 | | | | | — | | | — | | | | | — | | | | | — | | | | | $(3.15) | | | 6j | ||||
Diluted | | | $7.92 | | | | | — | | | — | | | | | — | | | | | — | | | | | $(3.15) | | | 6j | ||||
Shares used in computing per share amounts: | | | | | | | | | | | | | | | | | | | | | | | |||||||||||
Basic | | | 152,146 | | | | | — | | | — | | | | | — | | | | | — | | | | | 182,224 | | | |||||
Diluted | | | 155,195 | | | | | — | | | — | | | | | — | | | | | — | | | | | 182,224 | | |
(a) | Represents the reclassification of other receivables and current assets to accounts receivable, net. The balance reclassified pertains to receivables related to unrecognized revenue representing the current portion of billings made for customer contracts that have not yet been recognized as revenue by Ansys. |
(b) | Represents the reclassification of accounts payable, accrued bonuses and commissions, accrued income taxes, and other accrued expenses and liabilities to accounts payable and accrued liabilities. |
(c) | Represents the reclassification of current portion of operating lease liabilities from other accrued expenses and liabilities to operating lease liabilities. |
(d) | Represents the reclassification of non-current portion of deferred revenue from other long-term liabilities to long-term deferred revenue. |
(e) | Represents the reclassification of remaining balance after adjustment as discussed in note 3(a) in other receivables and current assets to prepaid and other current assets. The balance reclassified relates to income taxes receivable, including overpayments and refunds, and prepaid expenses and other current assets. |
(f) | Represents the adjustment to gross up accounts receivable and associated deferred revenue balances. Ansys follows an accounting policy to net down any accounts receivable related to invoices with due dates greater than three months from the period end date to the extent that related deferred revenue exists on the balance sheet, through a net down adjustment. Synopsys recognizes accounts receivable and related deferred revenue liability that are due within twelve months from the balance sheet date. |
(g) | Represents the reclassification of revenue from software licenses presented by Ansys as revenue from upfront products to align presentation with Synopsys. |
(h) | Represents the reclassification of cost of revenue related to software licenses to cost of revenue related to products. |
(i) | Represents the reclassification of selling, general and administrative expense to sales and marketing expense and general and administrative expense. |
(j) | Represents the reclassification of interest income and interest expense to other income (expense), net. |
| | (in thousands) | |
Estimated cash consideration(1) | | | $17,175,032 |
Estimated fair value of Synopsys common stock to be issued(2) | | | 17,001,525 |
Estimated fair value of assumed Ansys equity awards attributable to pre-combination service(3) | | | 211,973 |
Estimated repayment of Ansys' outstanding debt(4) | | | 754,419 |
Total estimated merger consideration | | | $35,142,949 |
Total cash consideration | | | 17,929,451 |
Total equity consideration | | | 17,213,498 |
Total estimated merger consideration | | | $35,142,949 |
(1) | Represents the estimated cash consideration to be paid, consisting of (i) approximately $17.1 billion calculated as a product of 87.0 million outstanding shares of Ansys common stock and cash consideration of $197.0 per share, (ii) approximately $0.3 million to settle all fractional shares derived upon exchange of Ansys common stock with Synopsys common stock, (iii) approximately $1.2 million to settle all specified RSUs that are granted to non-employee directors representing amounts attributable to pre-combination services and (iv) approximately $30.9 million associated with specified RSUs that are vested RSUs granted to non-continuing employees representing amounts attributable to pre-combination services. The amount does not include Ansys specified options because there are no outstanding Ansys specified options as of March 5, 2024. The amount of cash consideration to be paid is based on $197.0 per share of Ansys common stock. |
(2) | Represents the estimated fair value of approximately 30.1 million shares of Synopsys common stock estimated to be issued, calculated using the per share price of Synopsys common stock as of March 5, 2024. The fair value of Synopsys common stock to be issued consists of (i) approximately $17.0 billion for the shares of Ansys common stock, (ii) approximately $1.2 million associated with Ansys’ specified RSUs that are granted to non-employee directors representing amounts attributable to pre-combination services and (iii) approximately $30.6 million to settle all specified RSUs that are granted to non-continuing employees representing amounts attributable to pre-combination services. The amount does not include Ansys specified options because there are no outstanding Ansys specified options as of March 5, 2024. As outlined in the merger agreement, each share of Ansys common stock to be settled at closing will be exchanged for 0.3450 shares of Synopsys common stock. |
(3) | Represents the estimated fair value of Ansys options (that is not a specified options) and Ansys RSUs (other than specified RSUs) attributable to pre-combination services. As outlined in the merger agreement, each outstanding Ansys option (that is not a specified option), Ansys RSU (other than specified RSUs) and will be assumed by Synopsys and converted into a number of stock options and restricted stock unit awards denominated in shares of Synopsys common stock. Synopsys estimates that approximately 0.1 million of Synopsys options with an estimated fair value of $31.1 million will be issued in connection with the merger, with $31.1 million attributed to pre-combination services. The fair value of Ansys’ equity awards after their conversion into Synopsys equity awards attributable to post-combination service will be recognized as expense over the post-combination service period. Synopsys also estimates that approximately 0.9 million of Synopsys RSUs with an estimated fair value of $536.6 million will be issued in connection with the merger, with $180.8 million attributed to pre-combination services. |
(4) | Represents estimated payoff amount for the repayment of Ansys’ unsecured term loan facility. |
Change in Stock Price | | | Stock Price | | | Estimated Merger Consideration | | | Estimated Goodwill |
| | (in thousands, except stock price) | |||||||
Increase of 10% | | | 621.79 | | | $36,843,102 | | | $25,510,891 |
Decrease of 10% | | | 508.73 | | | $33,442,797 | | | $22,110,586 |
| | (in thousands) | |
Cash and cash equivalents | | | $703,911 |
Short-term investments | | | 189 |
Accounts receivable, net | | | 1,336,260 |
Prepaid and other current assets | | | 70,747 |
Property and equipment, net | | | 94,884 |
Operating lease right-of-use assets, net | | | 110,420 |
Intangible assets, net | | | 12,840,000 |
Other long-term assets | | | 220,702 |
Deferred income taxes | | | 164,227 |
Total assets | | | 15,541,340 |
Accounts payable and accrued liabilities | | | 408,566 |
Operating lease liabilities | | | 23,306 |
Deferred revenue | | | 632,259 |
Long-term operating lease liabilities | | | 100,505 |
Long-term deferred revenue | | | 77,159 |
Deferred income taxes | | | 2,876,054 |
Other long-term liabilities | | | 91,280 |
Total liabilities | | | 4,209,129 |
Net assets acquired(a) | | | 11,332,211 |
Estimated purchase consideration(b) | | | 35,142,949 |
Estimated goodwill(b) - (a) | | | $23,810,738 |
(a) | Represents the total merger consideration of $35.1 billion, consisting of (i) cash consideration comprising of (A) $17.1 billion, (B) approximately $0.3 million to settle all fractional shares derived upon exchange of Ansys common stock with the Synopsys common stock, (C) repayment of the outstanding balance of $754.4 million under Ansys’ senior unsecured term loan by Synopsys, and (ii) share-based consideration comprising of (A) issuance of approximately 30.1 million shares of Synopsys common stock with an estimated fair value of $17.0 billion, and (B) issuance of approximately 0.1 million and 0.9 million of Synopsys options and Synopsys RSUs, respectively with an estimated fair value of $31.1 million and $180.8 million attributable to pre-combination services, respectively. |
(b) | Reflects the adjustment to cash and cash equivalents and Synopsys’ retained earnings to record the estimated merger costs to be incurred by Synopsys in connection with the merger. |
(c) | Reflects the adjustment to cash and cash equivalents to record the estimated merger costs to be incurred by Ansys in connection with the merger. |
(d) | Synopsys expects to record a one-time post-combination cash expense of $9.0 million related to assumed severance costs. These payments are in addition to the accelerated vesting of stock-based compensation awards as mentioned in Note 5(l) below. |
(e) | Represents the net adjustment to the estimated fair value of property and equipment of Ansys. Preliminary property and equipment fair values in the pro forma financial information are provided in the table below. The depreciation expense related to these assets is reflected as a pro forma adjustment in the unaudited pro forma condensed combined statements of income, as further described in Note 6(b). |
Property and equipment, net | | | Estimated Fair Value (in thousands) | | | Estimated Useful Life (in years) |
Office furniture and equipment | | | $8,237 | | | 6 |
Computer hardware and software | | | 44,275 | | | 3 |
Buildings and improvements | | | 17,766 | | | 22 |
Leasehold improvements | | | 15,708 | | | 6 |
Land | | | 7,428 | | | n/a |
Site improvements | | | 1,470 | | | 5 |
Total | | | $94,884 | | | |
Eliminate historical Ansys property and equipment carrying value | | | 77,780 | | | |
Adjustment | | | $17,104 | | |
(f) | Represents the preliminary estimate of goodwill based on the preliminary purchase price allocation. |
(g) | Represents the derecognition of accounts receivable, prepaid and other current assets, other long-term assets, accounts payable and accrued liabilities, and deferred revenue in the unaudited pro forma condensed combined balance sheets arising from prior transactions between Ansys and Synopsys. |
(h) | Represents the net adjustment to the estimated fair value of intangible assets acquired in the merger. Preliminary identifiable intangible assets in the pro forma financial information are provided in the table below. The amortization related to these identifiable intangible assets is reflected as a pro forma |
Intangible Assets | | | Estimated Fair Value (in thousands) | | | Estimated Useful Life (in years) |
Developed software and core technologies | | | $6,500,000 | | | 7 |
Customer lists | | | 5,700,000 | | | 13 |
Order backlog | | | 310,000 | | | 2 |
Trade names | | | 330,000 | | | 10 |
Total | | | $12,840,000 | | | |
Eliminate historical Ansys intangible assets carrying value | | | 835,417 | | | |
Adjustment | | | $12,004,583 | | |
(i) | Represents the elimination of unamortized debt issuance costs of $1.1 million associated with Ansys’ unsecured term loan facility of $755.0 million, which will be paid off by Synopsys at the closing date, as further described in Note 5(j) below. |
(j) | Represents the elimination of outstanding principal balance and accrued interest related to Ansys’ unsecured term loan facility, which will be paid off concurrent with the closing of the merger. |
(k) | Represents the elimination of Ansys’ historical goodwill and equity balances. |
(l) | Represents the adjustment to Synopsys’ retained earnings to record a one-time post-combination expense of $45.0 million related to assumed severance costs for the acceleration of unvested equity awards and includes stock-based compensation expense associated with the post-combination portion of acquisition date fair value of an assumed settlement amount of $1.0 million for Ansys’ specified RSUs that are granted to non-employee directors. Because these awards will be settled at closing and require no further service, the entire post-combination portion of such awards is recognized as compensation expense immediately after the closing of the merger. |
(m) | Represents the adjustment to the deferred tax asset and the deferred tax liability balances associated with the incremental differences in the book and tax basis created from the preliminary purchase price allocation, primarily resulting from the closing date value of intangible assets. Deferred taxes are established based on a statutory tax rate based on jurisdictions where income is generated. The effective tax rate of Synopsys following the merger could be significantly different (either higher or lower) depending on post-acquisition activities, including repatriation decisions, cash needs and the geographical mix of income. This determination is preliminary and subject to change based upon the final determination of the fair value of the identifiable intangible assets and liabilities. |
(n) | Reflects a preliminary purchase accounting adjustment to record a $6.6 million unfavorable contractual lease balance when compared to market terms. |
(a) | Represents the adjustment to record elimination of historical amortization expense and recognition of new amortization expense related to identifiable intangible assets based on the estimated fair value. Amortization expense is calculated based on the estimated fair value of each of the identifiable intangible assets and the associated estimated useful life as discussed in Note 5(h) above and is allocated between amortization of intangible assets – cost of revenue and amortization of intangible assets – operating expenses based on the nature of the intangible assets acquired. |
| | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 | |||||||
| | Cost of Sales | | | Operating expenses | | | Cost of Sales | | | Operating expenses | |
| | (in thousands) | ||||||||||
Reversal of Ansys’ historical amortization expense | | | $(20,586) | | | $(5,914) | | | $(77,829) | | | $(20,345) |
Amortization of purchased identifiable intangible assets | | | 232,143 | | | 156,615 | | | 928,571 | | | 626,462 |
Change in intangible asset amortization expense | | | $211,557 | | | $150,701 | | | $850,742 | | | $606,117 |
(b) | Represents the adjustment to record elimination of historical depreciation expense and recognition of new depreciation expense based on the estimated fair value as of January 31, 2024. The depreciation of property and equipment is based on the estimated remaining useful lives of the assets as discussed in Note 5(e) above. Depreciation expense is allocated among products, maintenance and service (referred to as M&S), research and development (referred to as R&D), sales and marketing (referred to as S&M), and general and administrative (referred to as G&A) based upon the nature of activities associated with the use of the property and equipment. |
| | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 | |||||||||||||||||||||||||
| | Cost of revenue | | | Operating expenses | | | Cost of revenue | | | Operating expenses | |||||||||||||||||||
| | Products | | | M&S | | | R&D | | | S&M | | | G&A | | | Products | | | M&S | | | R&D | | | S&M | | | G&A | |
| | (in thousands) | ||||||||||||||||||||||||||||
Reversal of Ansys’ historical depreciation expense | | | $(19) | | | $(718) | | | $(2,771) | | | $(2,397) | | | $(1,084) | | | $(77) | | | $(3,044) | | | $(11,347) | | | $(10,188) | | | $(4,509) |
Depreciation of acquired property and equipment | | | 13 | | | 492 | | | 1,900 | | | 1,644 | | | 743 | | | 51 | | | 2,000 | | | 7,457 | | | 6,696 | | | 2,963 |
Change in depreciation expense | | | $(6) | | | $(226) | | | $(871) | | | $(753) | | | $(341) | | | $(26) | | | $(1,044) | | | $(3,890) | | | $(3,492) | | | $(1,546) |
(c) | Represents the adjustment to record the elimination of historical Ansys stock-based compensation expense, recognition of new stock-based compensation expense for the post-combination portion of Ansys’ RSUs. |
| | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 | |||||||||||||||||||
| | Cost of revenue | | | Operating expenses | | | Cost of revenue | | | Operating expenses | |||||||||||||
| | M&S | | | R&D | | | S&M | | | G&A | | | M&S | | | R&D | | | S&M | | | G&A | |
| | (in thousands) | ||||||||||||||||||||||
Post-combination stock-based compensation expense | | | $1,431 | | | $8,780 | | | $9,699 | | | $3,416 | | | $13,475 | | | $91,320 | | | $ 123,328 | | | $36,542 |
Reversal of Ansys’ historical stock-based compensation expense | | | (1,115) | | | (6,842) | | | (7,558) | | | (2,662) | | | (10,656) | | | (72,365) | | | (98,100) | | | (28,972) |
Excess fair value of the Synopsys awards over the Ansys awards | | | 261 | | | 1,601 | | | 1,769 | | | 623 | | | 4,172 | | | 25,597 | | | 28,279 | | | 9,959 |
Change in stock-based compensation expense | | | $577 | | | $3,539 | | | $3,910 | | | $1,377 | | | $6,991 | | | $44,552 | | | $53,507 | | | $17,529 |
(d) | Represents the reversal of Ansys’ historical interest expense, including the amortization of debt issuance costs. |
(e) | A statutory tax rate of approximately 21.0% is assumed for all pro forma adjustments. The statutory tax rate is not necessarily indicative of the effective tax rate of Synopsys following the merger, which could be significantly different depending on post-acquisition activities, including repatriation decisions, cash needs and the geographical mix of income. The income tax related adjustments for the year ended October 31, 2023, primarily relate to the additional interest expense of $1.1 billion, additional amortization expense of $1.5 billion and other miscellaneous adjustments aggregating to $317.8 million which had the impact of increasing the effective income tax rate to 43.8% from the customary effective income tax rate of 6.4% for Synopsys and 7.7% for Ansys. |
(f) | Represents an adjustment to record amortization expense for all unfavorable contractual lease terms when compared to market. |
(g) | Reflects the total estimated merger costs for Synopsys to be recognized in the condensed combined statements of income for the year ended October 31, 2023. Merger costs of $185.3 million are expensed and reflected as if incurred on November 1, 2022, the date the merger is assumed to have been completed for the purposes of the unaudited pro forma condensed combined statements of income. In addition, merger costs of $10.0 million are anticipated to be incurred in the three months after the assumed closing date of November 1, 2022, and are also reflected as an expense on the unaudited pro forma condensed combined statements of income for the year ended October 31, 2023. This is a non-recurring item. |
(h) | Represents the elimination of revenue and expenses in the unaudited pro forma condensed combined statements of income arising from prior transactions between Ansys and Synopsys. |
(i) | Represents one-time post-combination expense related cash payments of $9.0 million related to assumed severance costs. These payments are in addition to the accelerated vesting of stock-based compensation awards as mentioned in Note 5(c) above. |
(j) | Represents the pro forma basic net income/(loss) per share attributable to common stock calculated using the historical basic weighted average shares of Synopsys common stock outstanding, adjusted for additional shares to be issued to holders of Ansys common stock and holders of Ansys equity awards to complete the merger. Pro forma diluted net income/(loss) per share attributable to common stock is calculated using the historical diluted weighted average shares of Synopsys common stock outstanding, with consideration given to the potentially dilutive impact for the additional shares to be issued to holders of Ansys common stock and holders of Ansys equity awards, including the potential dilutive effect of the additional Synopsys RSUs to be issued in conjunction with the merger. All potentially dilutive awards were excluded from the computation of pro forma diluted net income/(loss) per share for the year ended October 31, 2023, because including them would have had an antidilutive effect. |
| | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 | |
| | (in thousands, except per share data) | ||||
Numerator: | | | | | ||
Pro forma net income/(loss) attributable to common stock | | | $ 176,968 | | | $ (574,031) |
Denominator: | | | | | ||
Historical Synopsys weighted average shares outstanding (basic) | | | 152,311 | | | 152,146 |
Shares of Synopsys common stock to be issued to Ansys stockholders pursuant to the merger agreement | | | 29,983 | | | 29,983 |
Shares of Synopsys common stock to be issued to holders of Ansys equity awards pursuant to the merger agreement | | | 95 | | | 95 |
Pro forma weighted average shares (basic) | | | 182,389 | | | 182,224 |
| | | | |||
Historical Synopsys weighted average shares outstanding (diluted) | | | 155,334 | | | 155,195 |
Shares of Synopsys common stock to be issued to Ansys stockholders pursuant to the merger agreement | | | 29,983 | | | 29,983 |
Shares of Synopsys common stock to be issued to holders of Ansys equity awards pursuant to the merger agreement | | | 95 | | | 95 |
Potentially dilutive impact of Synopsys’ options and restricted stock unit awards to be issued to replace Ansys’ options, restricted stock unit awards and performance stock unit awards | | | 922 | | | 603 |
Pro forma weighted average shares (diluted) | | | 186,334 | | | 185,876 |
| | | | |||
Pro forma shares used in computing pro forma net income/(loss) per share: | | | | | ||
Basic | | | 182,389 | | | 182,224 |
Diluted | | | 186,334 | | | 182,224 |
| | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 | |
| | (in thousands, except per share data) | ||||
Pro forma net income/(loss) per share attributable to common stock: | | | | | ||
Basic | | | $ 0.97 | | | $ (3.15) |
Diluted | | | $ 0.95 | | | $ (3.15) |
A. | Debt Obligations |
(in thousands) | | | Current Portion | | | Long Term |
Issuance of new debt: | | | | | ||
Borrowings under the debt commitment letter commitments | | | $ 11,700,000 | | | $— |
Borrowings under the term loan credit agreement | | | — | | | 4,300,000 |
Borrowings under the revolving credit facility | | | — | | | 850,000 |
Debt issuance costs | | | (369,750) | | | (5,585) |
Pro forma adjustments for new issuance(1) | | | $11,330,250 | | | $ 5,144,415 |
(1) | Reflects the assumption of newly raised borrowings under the debt commitment letter commitments, term loan credit agreement and revolving credit facility with a total principal amount of $16.9 billion to be issued by Synopsys to fund the merger and pay down existing Ansys debt as described in Note 4 above, net of a total of $375.3 million debt issuance costs. |
B. | Interest Expense |
(in thousands) | | | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 |
Interest on borrowings under the debt commitment letter commitments(1) | | | $ 218,772 | | | $875,084 |
Interest on borrowings under the term loan credit agreement(2) | | | 45,793 | | | 182,604 |
Interest on borrowings under the revolving credit facility(3) | | | 8,773 | | | 34,995 |
Total pro forma interest expense adjustment | | | $ 273,338 | | | $ 1,092,683 |
(1) | Represents additional interest expense and amortization of debt issuance costs on the $11.7 billion of borrowings assumed under the debt commitment letter commitments using the effective interest rate method, with the weighted-average interest rate equal to 7.71%. |
(in thousands) | | | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 |
Increase of 0.125% | | | $3,546 | | | $14,183 |
Decrease of 0.125% | | | $ (3,546) | | | $ (14,183) |
(2) | Represents additional interest expense and amortization of debt issuance costs on the $4.3 billion borrowings under the term loan credit agreement. The adjustment assumes the borrowings were obtained on November 1, 2022, and in two tranches of $1.5 billion and $2.8 billion for two-year and three-year terms, respectively. Interest expense is calculated using the effective interest rate method, with the weighted average rate equal to 4.23% and 4.35% for the two-year and three-year tranches, respectively. |
(in thousands) | | | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 |
Increase of 0.125% | | | $1,328 | | | $5,294 |
Decrease of 0.125% | | | $ (1,328) | | | $ (5,294) |
(3) | Represents additional interest expense and amortization of debt issuance costs on the $850.0 million borrowings under the revolving credit facility. Interest expense is calculated using the effective interest rate method, with the weighted average rate equal to 4.18%. |
(in thousands) | | | For the Three Months Ended January 31, 2024 | | | For the Year Ended October 31, 2023 |
Increase of 0.125% | | | $263 | | | $1,048 |
Decrease of 0.125% | | | $ (263) | | | $ (1,048) |
Name | | | Position |
Ajei S. Gopal(1) | | | President and Chief Executive Officer |
Nicole Anasenes(1), (2) | | | Former Senior Vice President of Finance and Chief Financial Officer |
Rachel Pyles(2) | | | Senior Vice President of Finance and Chief Financial Officer |
Shane Emswiler(1) | | | Senior Vice President, Products |
Walt Hearn(1) | | | Senior Vice President of Worldwide Sales and Customer Excellence |
Janet Lee(1) | | | Senior Vice President, General Counsel and Secretary |
(1) | Each individual will be a “named executive officer” for purposes of Ansys’ annual proxy statement for fiscal year ended December 31, 2023 to be filed with the SEC. |
(2) | On February 15, 2024, Ansys and Ms. Anasenes entered into a Transition Agreement, pursuant to which, Ms. Anasenes resigned as Chief Financial Officer and Senior Vice President of Finance effective as of February 22, 2024 and will remain an employee of Ansys until June 7, 2024, following which she will transition to providing consulting services to Ansys until August 8, 2024 pursuant to a consulting agreement. Effective as of her resignation from the position of Chief Financial Officer and Senior Vice President of Finance, Ms. Anasenes is no longer eligible to participate in the Ansys Executive Severance Plans. On February 15, 2024, the Ansys board of directors appointed Rachel Pyles as Chief Financial Officer and Senior Vice President of Finance of Ansys, effective as of February 22, 2024. |
Name | | | |
Ronald Hovsepian | | | |
Claire Bramley | | | |
Robert Calderoni | | | |
Dr. Anil Chakravarthy | | | |
Glenda Dorchak | | | |
Jim Frankola | | | |
Dr. Alec Gallimore | | | |
Barbara Scherer | | | |
Ravi Vijayaraghavan | | |
• | The effective time is March 11, 2024, which is the assumed date of the closing of the merger solely for purposes of the disclosure in this section; |
• | The relevant price per share of Ansys common stock is $332.79, which is the average closing price per share of Ansys common stock as reported on the Nasdaq over the first five business days following the first public announcement of the merger on January 16, 2024; |
• | Each executive officer of Ansys experiences a qualifying termination of employment (i.e., a termination of employment by Ansys and/or Synopsys without “cause” or, to the extent applicable, by the executive officer for “good reason,” as such terms are defined in the relevant plans and agreements) immediately following the assumed effective time of March 11, 2024; |
• | At the effective time, the performance metrics applicable to Ansys PSUs will convert to time-vesting Ansys RSUs at the target level of performance; |
• | The potential payments and benefits described in this section are not subject to a “cutback” to avoid the “golden parachute” excise tax that may be imposed under Section 4999 of the Code; and |
• | No director or executive officer receives any additional equity grants or other awards on or prior to the assumed effective time of March 11, 2024. |
• | a lump sum amount equal to one and a half (1.5) times the amount of the executive officer’s base salary in effect immediately prior to the termination, plus 100% of the executive officer’s annual target bonus; |
• | an amount in cash equal to any annual cash incentive earned in the fiscal year prior to the fiscal year in which the termination date occurs, to the extent unpaid as of the date of termination; |
• | a pro-rata portion of the earned but unpaid portion of the annual target bonus for the year of termination; |
• | a lump sum amount equal to twelve (12) months of COBRA premiums applicable to health, dental and vision insurance plans in which the executive officer was participating immediately prior to the termination; and |
• | accelerated vesting of any then-unvested equity awards, as discussed above in “—Interests of Ansys’ Directors and Executive Officers in the Merger — Treatment and Quantification of Ansys Equity Awards.” |
• | a lump sum in an amount equal to two (2) times the sum of (i) Dr. Gopal’s then-current annual base salary (or, if higher, his annual base salary in effect immediately prior to the effective time), plus (ii) Dr. Gopal’s target annual cash incentive for the then-current fiscal year; |
• | an amount in cash equal to any annual cash incentive earned in the fiscal year prior to the fiscal year in which the termination date occurs, to the extent unpaid as of the date of termination; |
• | a pro-rata portion of the earned but unpaid portion of the annual target bonus for the year of termination; |
• | a lump sum amount equal to twenty-four (24) months of COBRA premiums applicable to health, dental and vision plans in which Dr. Gopal was participating immediately prior to the termination; and |
• | accelerated vesting of then-unvested equity awards, as discussed above in “—Interests of Ansys’ Directors and Executive Officers in the Merger—Treatment and Quantification of Ansys Equity Awards.” |
• | The effective time is March 11, 2024, which is the assumed date of closing of the merger solely for purposes of the disclosure in this section; |
• | Each named executive officer of Ansys experiences a qualifying termination of employment (i.e., a termination of employment by Ansys and/or Synopsys without “cause” or, to the extent applicable, by the executive officer for “good reason,” as such terms are defined in the relevant plans and agreements) immediately following the assumed effective time of March 11, 2024; |
• | At the effective time, the performance metrics applicable to Ansys PSUs will convert to time-vesting Ansys RSUs at the target level of performance; |
• | The potential payments and benefits described in this section are not subject to a “cutback” to avoid the “golden parachute” excise tax that may be imposed under Section 4999 of the Code; and |
• | No named executive officer receives any additional equity grants or other awards on or prior to the assumed effective time of March 11, 2024. |
Name | | | Cash ($)(1) | | | Equity ($)(2) | | | Perquisites/Benefits ($)(3) | | | Total ($)(4) |
Ajei S. Gopal | | | $6,899,819 | | | $65,425,848 | | | $37,350 | | | $72,363,017 |
Nicole Anasenes | | | — | | | $11,944,831 | | | — | | | $11,944,831 |
Shane Emswiler | | | $1,532,549 | | | $16,771,618 | | | $18,360 | | | $18,322,527 |
Walt Hearn | | | $1,449,072 | | | $15,499,029 | | | $21,787 | | | $16,969,888 |
Janet Lee | | | $1,461,751 | | | $9,691,510 | | | $18,360 | | | $11,171,621 |
(1) | Cash. Represents the cash severance payable to the named executive officers (other than Ms. Anasenes, who is not eligible to receive cash severance following her resignation as an officer of Ansys) upon a termination of employment by Ansys and/or Synopsys without cause or by such named executive officer for good reason, in each case, pursuant to the Tier 2 Executive Severance Plan (or, in the case of Dr. Gopal, his employment agreement with Ansys). The cash severance payable to the named executive officers are “double-trigger” payments, which means that the amounts will become payable only upon a qualifying termination of employment within ninety (90) days prior to and eighteen (18) months following the closing of the merger (and for Dr. Gopal, sixty (60) days prior to the effective date of the merger agreement and eighteen (18) months following the closing of the merger). For further details regarding the cash severance that may become payable to Ansys’ named executive officers, see “—Interests of Ansys’ Directors and Executive Officers in the Merger—Potential Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time.” The estimated amount of each such payment is shown in the following table: |
Name | | | Base Salary Severance ($) | | | Annual Target Bonus Severance ($) | | | Prior Year Bonus (earned but unpaid) ($) | | | Prorated Annual Target Bonus ($) | | | Total ($) |
Ajei S. Gopal | | | $1,700,000 | | | $2,550,000 | | | $2,402,483 | | | $247,336 | | | $6,899,819 |
Shane Emswiler | | | $605,181 | | | $302,591 | | | $566,078 | | | $58,699 | | | $1,532,549 |
Walt Hearn | | | $577,500 | | | $288,750 | | | $526,807 | | | $56,014 | | | $1,449,071 |
Janet Lee | | | $579,375 | | | $289,688 | | | $536,492 | | | $56,196 | | | $1,461,751 |
(2) | Equity. Represents the value of the Ansys RSUs and Ansys PSUs that will vest and become payable upon a termination of employment by Ansys and/or Synopsys (i) without cause or by such named executive officer for good reason, in each case, pursuant to the Tier 2 Executive Severance Plan, (ii) for Dr. Gopal, without cause or by such named executive officer for good reason, in each case, pursuant to his employment agreement with Ansys, and (iii) for Ms. Anasenes, without cause pursuant to the terms of the applicable award agreements. The accelerated vesting of unvested Ansys RSUs and unvested Ansys PSUs held by the named executive officers are “double-trigger” payments, which means that they will vest and become payable only upon a qualifying termination of employment within (i) ninety (90) days prior to and eighteen (18) months following the closing of the merger, (ii) for Dr. Gopal, sixty (60) days prior to the effective date of the merger agreement and eighteen (18) months following the closing of the merger, and (iii) for Ms. Anasenes, within eighteen (18) months following the closing of the merger. For further details regarding the treatment of the Ansys equity awards held by the named executive officers, see “—Interests of Ansys’ Directors and Executive Officers in the Merger —Treatment and Quantification of Ansys Equity Awards,” and “—Interests of Ansys’ Directors and Executive Officers in the Merger—Potential Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time.” The estimated amount of each such payment is shown in the following table: |
| | Unvested Ansys PSUs | | | Unvested Ansys RSUs | | | ||||||||
Name | | | Number (#) | | | Value ($) | | | Number (#) | | | Value ($) | | | Total ($) |
Ajei S. Gopal | | | 94,075 | | | $31,307,219 | | | 102,523 | | | $34,118,629 | | | $65,425,848 |
Nicole Anasenes | | | 26,035 | | | $8,664,188 | | | 9,858 | | | $3,280,644 | | | $11,944,832 |
Shane Emswiler | | | 24,799 | | | $8,252,859 | | | 25,598 | | | $8,518,758 | | | $16,771,617 |
Walt Hearn | | | 23,117 | | | $7,693,106 | | | 23,456 | | | $7,805,922 | | | $15,499,028 |
Janet Lee | | | 12,384 | | | $4,121,271 | | | 16,738 | | | $5,570,239 | | | $9,691,510 |
(3) | Perquisites/Benefits. Represents the estimated total cost to Ansys and/or Synopsys of the continued medical, dental and vision benefits provided to the named executive officers (other than Ms. Anasenes, who is not eligible to receive cash severance following her resignation as an officer of Ansys) pursuant to the Tier 2 Executive Severance Plan (or, in the case of Dr. Gopal, his employment agreement with Ansys). The amounts shown in this column are “double-trigger” and will not be payable unless the named executive officer’s employment is terminated by the employer without cause or by the named executive officer for good reason, in each case within ninety (90) days prior to and eighteen (18) months following the closing of the merger (and for Dr. Gopal, sixty (60) days prior to the effective date of the merger agreement and eighteen (18) months following the closing of the merger). For further details regarding these benefits, see “—Interests of Ansys’ Directors and Executive Officers in the Merger—Potential Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time.” |
(4) | Section 280G. The total amounts do not reflect any reductions to “parachute payments” as defined by Code Section 280G in order to avoid any applicable excise tax thereunder. A definitive analysis of the need, if any, for such reductions will depend on the effective time, the date of termination (if any) of the named executive officer and certain other assumptions used in the applicable calculations. |
| | Ansys | | | Synopsys | |
Authorized Capital Stock | | | Ansys has authority to issue 302,000,000 shares of common stock, $0.01 par value per share, and 2,000,000 shares of preferred stock, $0.01 par value per share. As of the record date, Ansys had 87,299,981 shares of Ansys common stock and no shares of preferred stock issued and outstanding. | | | Synopsys has authority to issue 400,000,000 shares of common stock, $0.01 par value per share, and 2,000,000 shares of preferred stock, $0.01 par value per share. |
| | | | |||
Preferred Stock | | | The Ansys board of directors is authorized to provide for the issuance of shares of preferred stock from time to time in one or more series, and authorized to fix and determine the relative rights and preferences between different series of preferred stock, and to fix or alter the number of shares comprising any such series. | | | The Synopsys board of directors is authorized to provide for the issuance of shares of preferred stock from time to time in one or more series, and authorized to fix and alter the preferences, privileges and restrictions granted to or imposed upon any such series and the number of shares constituting any such series and the designation thereof, or of any of them. |
| | | | |||
Voting Rights | | | Each holder of Ansys stock is entitled to one vote for each share of stock held by such stockholder. | | | Each holder of Synopsys common stock is entitled to one vote for each share of common stock held by such stockholder. |
| | | | |||
Dividend Rights | | | The Ansys charter provides that the Ansys board of directors may declare and pay dividends for payment upon the common stock, but only out of assets or funds available for the payment of dividends as provided by law. Under the DGCL, the directors of a corporation may declare and pay dividends upon the shares of its capital stock either out of its surplus or, if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. | | | The Synopsys bylaws provide that the Synopsys board of directors may declare dividends upon the capital stock of the corporation, subject to the provisions of the Synopsys charter. The Synopsys bylaws provide that the Synopsys board of directors may set aside out of any funds of the corporation available for dividends such sum or sums as the board of directors thinks, in its absolute discretion, proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purposes as the board of directors thinks conducive to the interest of the corporation, and the Synopsys board of directors may modify or abolish any such reserve in the manner in which it was created. |
| | | | |||
Other Rights | | | Holders of Ansys common stock are not entitled to preemptive rights with respect to any shares which may be issued, and there are no conversion rights or redemption, purchase, retirement or sinking fund | | | Holders of Synopsys common stock are not entitled to preemptive rights with respect to any shares which may be issued, and there are no conversion rights or redemption, purchase, retirement or sinking fund |
| | Ansys | | | Synopsys | |
| | provisions with respect to Ansys common stock. | | | provisions with respect to Synopsys common stock. | |
| | | | |||
Class of Directors | | | The Ansys board of directors is currently divided into three classes, as nearly equal in number as possible. At the 2023 annual meeting, Ansys stockholders approved amendments to the Ansys charter to phase out the classified board so that the Ansys board of directors is fully declassified from and after the 2026 annual meeting of the stockholders of Ansys, the successors of the class of directors whose term expires at that meeting are elected by a plurality vote of all votes cast at such meeting in a contested election to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election. Beginning with the 2024 annual meeting, the directors whose term expires at that meeting are to be elected for a one-year term that expires at the 2025 annual meeting. At the 2025 annual meeting (if held), the directors whose term expires at that meeting (including the directors who were elected at the 2024 annual meeting) are to be elected for a one-year term that expires at the 2026 annual meeting. At the 2026 annual meeting (if held), all directors will have expiring terms and are to be elected for one-year terms expiring at the 2027 annual meeting. | | | Synopsys does not have a classified board. |
| | | | |||
Number of Directors | | | Under the Ansys charter and bylaws, the number of directors constituting the Ansys board of directors will be as determined from time to time by resolution of a majority of the Ansys board of directors. At present, Ansys has ten directors. | | | Under the Synopsys charter and bylaws, the number of directors constituting the Synopsys board of directors will be determined by a bylaw or amendment thereof or a resolution of the board of directors. At present, Synopsys has eleven directors. |
| | | | |||
Election of Directors | | | Under the Ansys charter and bylaws, in an uncontested election of directors, any nominee for director shall be elected to the Ansys board of directors if the votes cast for such nominee’s election exceed the votes against such nominee’s election. In a contested election of directors where there are more nominees for election than positions on the Ansys board of directors to | | | Each director is elected by a majority of the votes cast by the stockholders at a meeting for the election of directors at which a quorum is present; except that, if the number of nominees for election at any such meeting exceeds the number of directors to be elected at such meeting, each director to be so elected will be elected by a plurality of the votes cast by stockholders at such meeting. If directors |
| | Ansys | | | Synopsys | |
| | be filled by election at that meeting, directors are elected by a plurality of the votes cast by the stockholders at a meeting at which a quorum is present. Ansys stockholders do not have cumulative voting rights. | | | are to be elected by a plurality of the votes cast, stockholders will not be permitted to vote against a nominee, and will only include votes “for” and votes to withhold authority. Synopsys stockholders do not have cumulative voting rights. | |
| | | | |||
Term of Office | | | Currently, Ansys directors are divided into three classes with each class consisting of as nearly as possible one third of the total number of directors. Each director currently serves a three-year term. Beginning with the 2024 annual meeting, the directors whose term expires at that meeting are to be elected for a one-year term that expires at the 2025 annual meeting. At the 2025 annual meeting (if held), the directors whose term expires at that meeting (including the directors who were elected at the 2024 annual meeting) are to be elected for a one-year term that expires at the 2026 annual meeting. At the 2026 annual meeting (if held), all directors will have expiring terms and are to be elected for one-year terms expiring at the 2027 annual meeting. Each director will hold office until such director’s term expires and until a successor has been duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal. | | | The Synopsys bylaws provide for all directors to be elected at each annual meeting for a term of one year, and each director elected will hold office until his or her successor is elected and qualified or until his or her death, resignation or removal. |
| | | | |||
Removal of Directors | | | Under the Ansys charter and bylaws, any director may be removed from office with or without cause (except that any director who is serving a three-year term prior to the 2026 annual meeting of stockholders may be removed only for cause) and upon the affirmative vote of a majority of the total votes which would be eligible to be cast by stockholders in the election of such director. At least 30 days prior to any meeting of stockholders at which it is proposed that any director may be removed from office, written notice of such proposed removal shall be sent to the director whose removal will be considered at the meeting. | | | Under the Synopsys bylaws, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of Synopsys shares entitled to vote at an election of directors. |
| | Ansys | | | Synopsys | |
| | | | |||
Filling Vacancies on the Board | | | Vacancies on the Ansys board of directors are filled by a majority of the remaining directors, even if less than a quorum. | | | Under the Synopsys bylaws, vacancies may be filled only by vote of at least two-thirds (2/3rds) of the directors then in office, though less than a quorum, or by a sole remaining director, except that in the event a director is removed by the stockholders for cause, the stockholders will be entitled to fill the vacancy created as a result of such removal. |
| | | | |||
Director Nominations and Stockholder Proposals | | | The Ansys bylaws require timely notice of the nomination, other than by or at the direction of the Ansys board of directors, of candidates for election as directors, as well as for other stockholder proposals, to be considered at special meetings of stockholders. To be timely, such stockholder’s notice complying with the applicable requirements under the Ansys bylaws must be delivered to or mailed and received by the Ansys at its principal executive office not less than 75 days nor more than 120 days prior to the anniversary date of the previous year’s annual meeting, except that in the event that the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, to be timely, a stockholder’s notice must be delivered to, or mailed and received by Ansys at its principal executive office not later than the close of business on the later of (i) the 75th day prior to the scheduled date of such annual meeting or (ii) the 15th day following the day on which public announcement of the date of such annual meeting is first made by Ansys. Notice of all special meetings of stockholders shall be given in the same manner as provided for annual meetings except that the written notice of all special meetings shall state the purpose or purposes for which the meeting has been called. | | | The Synopsys bylaws require advance notice for nominations for election to the Synopsys board of directors to be properly brought before an annual meeting or a special meeting of stockholders, as well as for other stockholder proposals to be properly brought before an annual meeting of stockholders. In the case of an annual meeting of stockholders, to be timely, generally, notice for nominations for election to the Synopsys board of directors or for other stockholder proposals, in each case, complying with the applicable notice requirements under the Synopsys bylaws, must be delivered to the secretary of Synopsys at the principal executive offices of Synopsys not later than the close of business on the 120th day nor earlier than the close of business on the 150th day prior to the first anniversary of the date on which Synopsys released its proxy materials to its stockholders for the prior year’s annual meeting of stockholders or any longer period provided for by applicable law. In the case of a special meeting of stockholders, to be timely, notice for nominations complying with the applicable notice requirements under the Synopsys bylaws must be delivered to the secretary of Synopsys at the principal executive offices of Synopsys not earlier than the close of business on the 120th day prior to such special meeting and not later than the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Synopsys board of |
| | Ansys | | | Synopsys | |
| | | | directors to be elected at such meeting. | ||
| | | | |||
Special Meetings of Stockholders | | | Under the Ansys bylaws, special meetings of the stockholders of Ansys may be called only by the Ansys board of directors pursuant to a resolution approved by the affirmative vote of a majority of directors then in office. Only those matters set forth in the notice of the special meeting may be considered or acted upon at the special meeting. | | | The Synopsys bylaws provide that special meetings of stockholders may be called by (i) the chairman, (ii) the president, (iii) the chief executive officer, (iv) the secretary of Synopsys at the written request of holders of not less than 15% of all outstanding shares of capital stock of Synopsys held for not less than 1 year prior to the date such request is delivered or (v) the chairman, the president or the secretary at the request in writing of a majority of the Synopsys board of directors. Under the Synopsys bylaws, the only matters that may be brought before a special meeting of stockholders are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting. The Synopsys board of directors will determine the time and place of such special meeting; provided, however, that the date of any such special meeting will not be more than 90 days after the date on which the relevant notice of meeting request has been delivered to the secretary of Synopsys in accordance with the Synopsys bylaws. |
| | | | |||
Quorum | | | Under the Ansys bylaws, the holders of a majority of the voting power of the total outstanding shares of voting stock of Ansys issued, outstanding, and entitled to vote at a meeting of stockholders, represented in person or by proxy at such meeting shall constitute a quorum; but if less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section 5, Article I of the Ansys bylaws. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave | | | Under the Synopsys bylaws, the holders of a majority of Synopsys stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum at all meetings of the stockholders for the transaction of business. If quorum is not present or represented at any meeting of the stockholders, the stockholders entitled to vote at such meeting, present in person or represented by proxy, will have power to adjourn the meeting from time to time by a vote of the holders of a majority of the shares present in person, without notice other than announcement at the meeting, until a quorum is present or represented, but no other business shall be transacted at such meeting. At such adjourned meeting at which a quorum is present or represented, any |
| | Ansys | | | Synopsys | |
| | less than a quorum. | | | business may be transacted which might have been transacted at the meeting as originally notified. If the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the meeting. | |
| | | | |||
Written Consent by Stockholders | | | Any action required or permitted to be taken by Ansys stockholders at any annual or special meeting must be effected only at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent in lieu of a meeting of stockholders. | | | Stockholders may not take any action by written consent in lieu of a meeting. |
| | | | |||
Business Combinations with Interested Stockholders | | | Section 203 of the DGCL generally prohibits “business combinations,” including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder who beneficially owns 15% or more of a corporation’s voting stock, within three years after the person or entity becomes an interested stockholder, unless: (i) the board of directors of the target corporation has approved, before the acquisition time, either the business combination or the transaction that resulted in the person becoming an interested stockholder, (ii) upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owns at least 85% of the corporation’s voting stock (excluding shares owned by directors who are officers and shares owned by employee stock plans in which participants do not have the right to determine confidentially whether shares will be tendered in a tender or exchange offer) or (iii) after the person or entity becomes an interested stockholder, the business combination is approved by the board of directors and authorized at a meeting of stockholders by the affirmative vote of at least 66 2/3% of the outstanding voting stock not owned by the interested stockholder. Ansys has not opted out of this provision. | | | Section 203 of the DGCL generally prohibits “business combinations,” including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder who beneficially owns 15% or more of a corporation’s voting stock, within three years after the person or entity becomes an interested stockholder, unless: (i) the board of directors of the target corporation has approved, before the acquisition time, either the business combination or the transaction that resulted in the person becoming an interested stockholder, (ii) upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owns at least 85% of the corporation’s voting stock (excluding shares owned by directors who are officers and shares owned by employee stock plans in which participants do not have the right to determine confidentially whether shares will be tendered in a tender or exchange offer) or (iii) after the person or entity becomes an interested stockholder, the business combination is approved by the board of directors and authorized at a meeting of stockholders by the affirmative vote of at least 66 2/3% of the outstanding voting stock not owned by the interested stockholder. Synopsys has not opted out of this provision. |
| | | |
| | Ansys | | | Synopsys | |
Limitations of Personal Liability of Directors | | | As permitted by Section 102(b)(7) of the DGCL, the Ansys charter eliminates the liability of a director to the corporation or its stockholders for monetary damages for such breach of fiduciary duty as a director, except for liabilities arising (i) from any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) from acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL; or (iv) from any transaction from which the director derived an improper personal benefit. | | | As permitted by Section 102(b)(7) of the DGCL, the Synopsys charter eliminates the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL; or (iv) for any transaction from which the director derived an improper personal benefit. |
| | | | |||
Indemnification | | | The Ansys bylaws require Ansys to indemnify to the fullest extent authorized by the DGCL any officer or director of Ansys against any and all expenses incurred by such officer or director in connection with any proceeding in which such officer is involved as a result of serving or having served (i) as an officer or employee of Ansys, (ii) as a director, officer, or employee of any subsidiary of the corporation, or (iii) in any capacity with any other corporation, organization, partnership, joint venture, trust or other entity at the written request or direction of Ansys. The Ansys board of directors may also indemnify non-officer employees to the fullest extent authorized by the DGCL against any and all expenses incurred by such non-office employee in connection with any proceeding in which such officer is involved as a result of serving or having served (i) as a non-officer employee of Ansys, (ii) as a director, officer, or employee of any subsidiary of Ansys, or (iii) in any capacity with any other corporation, organization, partnership, joint venture, trust or other entity at the written request or direction of Ansys. Ansys may maintain insurance covering its directors and officers, or non-officer employees against certain liabilities incurred by them in their capacities as such, whether or not Ansys could indemnify such person against such liability under the DGCL or the Ansys bylaws. | | | The Synopsys bylaws require Synopsys to indemnify to the full extent permitted by, and in the manner permissible under, the DGCL, any person made, or threatened to be made, a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, his or her testator or intestate is or was a director or officer of Synopsys or any predecessor of Synopsys, or served any other enterprise as a director or officer at the request of Synopsys or any predecessor of Synopsys. The Synopsys board of directors may also indemnify any other person made a party to any action, suit or proceeding by reason of the fact that he or she, his or her testator or intestate, is or was an employee or agent of Synopsys. Synopsys maintains insurance covering its directors and officers against certain liabilities incurred by them in their capacities as such. |
| | Ansys | | | Synopsys | |
| | | | |||
Amendments to the Charter | | | The Ansys charter provides that no amendment or repeal of the charter may be made unless first approved by the Ansys board of directors and except as otherwise provided under the DGCL, thereafter approved by the stockholders. Whenever any vote of the holders of voting stock is required, and in addition to any other vote of holders of voting stock that is required by this charter or by law, the affirmative vote of a majority of the total votes eligible to be cast by holders of voting stock with respect to such amendment or repeal, voting together as a single class, at a duly constituted meeting of the stockholders called for expressly such purpose shall be required to maned or repeal any provisions of the charter. | | | The Synopsys charter provides reserves for Synopsys the right to amend, alter, change or repeal any provision contained in the charter, in the manner prescribed by law. Under the DGCL, the amendment of the certificate of incorporation of a corporation requires the approval a majority of the outstanding stock entitled to vote upon the proposed amendment, and a majority of the outstanding stock of each class entitled to vote upon the proposed amendment. |
| | | | |||
Amendments to the Bylaws | | | The Ansys charter and bylaws provide that the Ansys board of directors is authorized to amend or repeal the Ansys bylaws. The Ansys charter and bylaws provide that the Ansys bylaws may be amended or repealed by the affirmative vote of holders of the majority of the total votes eligible to be cast on such amendment or repeal by holders of voting stock, voting together as a single class. | | | The Synopsys charter provides the Synopsys board of directors is authorized to make, repeal, alter, amend or rescind the Synopsys bylaws. The Synopsys bylaws provide that that any bylaw, including the Synopsys bylaws may be adopted, amended or repealed by the vote of the holders of a majority of the shares of Synopsys then entitled to vote at an election of directors, or by vote of the Synopsys board of directors (or by their written consent). |
| | | | |||
Forum Selection | | | The Ansys bylaws provide that, unless Ansys consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of Ansys, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Ansys to Ansys or Ansys’ stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the charter or bylaws, or (iv) any action asserting a claim against Ansys governed by the internal affairs doctrine. | | | The Synopsys bylaws provide that, unless Synopsys consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the corporation to the corporation or the corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the charter or the bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. |
• | the Ansys stockholder or beneficial owner of shares of Ansys common stock must deliver to Ansys a written demand for appraisal before the vote on the merger agreement proposal at the Ansys special meeting, which written demand must reasonably inform Ansys of the identity of the Ansys stockholder or beneficial owner of Ansys common stock and that the Ansys stockholder or beneficial owner of Ansys common stock intends to demand appraisal of their shares. This written demand for appraisal must be in addition to and separate from any proxy or vote abstaining from or voting against the merger agreement proposal. Voting “AGAINST” or failing to vote “FOR” the merger agreement proposal by itself does not constitute a demand for appraisal within the meaning of Section 262 of the DGCL; |
• | in the case of an Ansys stockholder of record, the stockholder must not vote, or abstain from voting, in favor of the merger agreement proposal; if a beneficial owner of Ansys common stock, such person or entity must not instruct their broker, bank or other nominee to vote their share(s), or abstain from voting, in favor of the merger agreement proposal; |
• | the Ansys stockholder or beneficial owner of Ansys common stock must continuously hold or beneficially own, as applicable, the shares of Ansys common stock from the date of making the demand through the effective time (an Ansys stockholder or beneficial owner of Ansys common stock will lose appraisal rights if the Ansys stockholder or beneficial owner of Ansys common stock transfers the shares before the effective time); and |
• | the Ansys stockholder, the beneficial owner of Ansys common stock or the surviving corporation in the merger must file a petition in the Court of Chancery requesting a determination of the fair value of the shares within 120 days after the effective time. The surviving corporation is under no obligation to file any such petition and has no intention of doing so. |
• | all persons known by Ansys to own beneficially 5% or more of Ansys outstanding common stock; |
• | each member of the Ansys board of directors; |
• | each of the named executive officers of Ansys; and |
• | all members of the Ansys board of directors and Ansys’ executive officers as a group. |
Name and Address | | | Number of Shares Beneficially Owned(1) | | | Approximate Percent of Class |
Certain beneficial owners: | | | | | ||
1. BlackRock, Inc. 50 Hudson Yards New York, New York 10001 | | | 10,605,414(2) | | | 12.1% |
2. The Vanguard Group, Inc. 100 Vanguard Blvd. Malvern, Pennsylvania 19355 | | | 10,161,054(3) | | | 11.6% |
| | | | |||
Directors and executive officers: | | | | | ||
Ajei S. Gopal | | | 269,750(4) | | | * |
Nicole Anasenes | | | 19,313(5) | | | * |
Shane Emswiler | | | 18,847(6) | | | * |
Walt Hearn | | | 12,025(7) | | | * |
Janet Lee | | | 16,570(8) | | | * |
Claire Bramley | | | 1,442(9) | | | * |
Robert Calderoni | | | 4,256(9) | | | * |
Anil Chakravarthy | | | 2,502(9) | | | * |
Glenda Dorchak | | | 3,049(9) | | | * |
Jim Frankola | | | 3,638(9) | | | * |
Alec Gallimore | | | 6,151(9) | | | * |
Ronald Hovsepian | | | 33,569(10) | | | * |
Barbara Scherer | | | 9,707(11) | | | * |
Ravi Vijayaraghavan | | | 4,256(9) | | | * |
All directors and executive officers as a group (14 persons) | | | 405,075(12) | | | * |
(1) | “Beneficial ownership” generally means any person who, directly or indirectly, has or shares voting or investment power with respect to a security or has the right to acquire such power within 60 days. Shares of Ansys common stock subject to options, warrants or rights that are currently exercisable or exercisable within 60 days of April 9, 2024 are deemed outstanding for computing the ownership percentage of the person holding such options, warrants or rights, but are not deemed outstanding for computing the ownership percentage of any other person. The amounts and percentages are based upon 87,299,891 shares of Ansys common stock outstanding as of April 9, 2024, unless otherwise indicated. |
(2) | Of the shares of Ansys common stock reported as beneficially owned, BlackRock, Inc. exercises sole power to vote 10,015,714 shares, and sole dispositive power over 10,605,414 shares. The total number of shares of Ansys common stock reported as beneficially owned is 10,605,414, as of December 31, 2023. The number of shares of Ansys common stock indicated is based on information reported in Schedule 13G/A filed by BlackRock, Inc. on January 23, 2024. |
(3) | Of the shares of Ansys common stock reported as beneficially owned, The Vanguard Group, Inc. exercises (a) shared power to vote 111,158 shares, (b) sole dispositive power over 9,801,256 shares, and (c) shared dispositive power over 359,798 shares. The total number of shares of Ansys common stock reported as beneficially owned is 10,161,054, as of December 29, 2023. The number of shares of Ansys common stock indicated is based on information reported in Schedule 13G/A filed by The Vanguard Group, Inc. on February 13, 2024. |
(4) | Amount includes 27,284 deferred stock units and 92,018 shares of common stock issuable upon the exercise of stock options that are currently exercisable, and 2,882 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(5) | Amount includes 894 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(6) | Amount includes 813 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(7) | Amount includes 2,617 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(8) | Amount includes 421 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024 |
(9) | Amount includes 967 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(10) | Amount includes 21,523 DSUs and 967 shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(11) | Amount includes 6,017 DSUs and 967 RSU shares of common stock issuable upon vesting of RSUs within 60 days of April 9, 2024. |
(12) | Includes directors, director nominees and current executive officers. Amount includes 54,824 DSU, 92,018 shares of common stock issuable upon the exercise of stock options that are currently exercisable, and 16,330 RSUs that will vest within 60 days of April 9, 2024. |
• | Annual Report on Form 10-K for the fiscal year ended October 28, 2023, filed with the SEC on December 12, 2023; |
• | Quarterly Report on Form 10-Q for the period ending February 3, 2024, filed with the SEC on February 23, 2024; |
• | The information in Synopsys’ definitive proxy statement on Schedule 14A for Synopsys’ April 10, 2024 annual meeting of stockholders, filed with the SEC on February 16, 2024; |
• | Current Reports on Form 8-K filed with the SEC on December 21, 2023, January 16, 2024, February 14, 2024, February 21, 2024, March 19, 2024, March 20, 2024, and March 25, 2024 (excluding any information and exhibits furnished under Item 2.02 or 7.01 thereof); and |
• | any description of shares of Synopsys common stock contained in a registration statement filed pursuant to the Exchange Act and any amendment or report filed for the purpose of updating such description. |
• | Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 21, 2024; |
• | The information in Ansys’ definitive proxy statement on Schedule 14A for Ansys’ June 7, 2024 annual meeting, filed with the SEC on April 10, 2024; and |
• | Current Report on Form 8-K filed with the SEC on February 20, 2024 (excluding any information and exhibits furnished under Item 2.01 or 7.01 thereof). |
| | | | | | Page | |||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | |
| | | | | | Page | |||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | ||||||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | |
| | | | | | ||||
| | | | | |
| | if to Parent or Merger Sub: | |||||||
| | | | | | ||||
| | | | Synopsys, Inc. | |||||
| | | | 675 Almanor Ave | |||||
| | | | Sunnyvale, CA 94085 | |||||
| | | | Attention: | | | John F. Runkel, Jr. | ||
| | | | | | Randy Tinsley | |||
| | | | | | Derek Chien | |||
| | | | Email: | | | XXXXXXXXXXXXX | ||
| | | | | | XXXXXXXXXXXXX | |||
| | | | | | XXXXXXXXXXXXX | |||
| | | | | | ||||
| | with a copy (which shall not constitute notice) to: | |||||||
| | | | | | ||||
| | | | Cleary Gottlieb Steen & Hamilton LLP | |||||
| | | | 650 California Street | |||||
| | | | San Francisco, CA 94108 | |||||
| | | | Attention: | | | Christopher R. Moore | ||
| | | | | | Paul J. Shim | |||
| | | | | | Benet J. O’Reilly | |||
| | | | Email: | | | chrmoore@cgsh.com | ||
| | | | | | pshim@cgsh.com | |||
| | | | | | boreilly@cgsh.com | |||
| | | | | | ||||
| | if to the Company: | |||||||
| | | | | | ||||
| | | | Ansys, Inc. | |||||
| | | | 2600 Ansys Drive | |||||
| | | | Canonsburg, PA 15317 | |||||
| | | | Attention: | | | Janet Lee | ||
| | | | Email: | | | XXXXXXXXXXXXX | ||
| | | | | | ||||
| | with a copy (which shall not constitute notice) to each of: | |||||||
| | | | | | ||||
| | | | Skadden, Arps, Slate, Meagher & Flom LLP | |||||
| | | | 525 University Ave. | |||||
| | | | Palo Alto, CA 94301 | |||||
| | | | Attention: | | | Mike Ringler | ||
| | | | | | Peter Jones | |||
| | | | Email: | | | mike.ringler@skadden.com | ||
| | | | | | peter.jones@skadden.com | |||
| | | | | | ||||
| | | | Goodwin Procter LLP | |||||
| | | | 100 Northern Avenue | |||||
| | | | Boston, MA 02110 | |||||
| | | | Attention: | | | Stuart M. Cable | ||
| | | | Email: | | | scable@goodwinlaw.com |
| | Synopsys, Inc. | ||||
| | | | |||
| | By: | | | /s/ Sassine Ghazi | |
| | Name: | | | Sassine Ghazi | |
| | Title: | | | Chief Executive Officer | |
| | | | |||
| | ALTA Acquisition Corp. | ||||
| | | | |||
| | By: | | | /s/ Sassine Ghazi | |
| | Name: | | | Sassine Ghazi | |
| | Title: | | | Authorized Signatory | |
| | | | |||
| | Ansys, Inc. | ||||
| | | | |||
| | By: | | | /s/ Ajei S. Gopal | |
| | Name: | | | Ajei S. Gopal | |
| | Title: | | | President and Chief Executive Officer |
1. | The name of the Corporation is ANSYS, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was January 12, 1994. The name under which the Company filed its original Certificate of Incorporation was SAS Holdings, Inc. |
2. | This Seventh Amended and Restated Certificate of Incorporation (this “Certificate”) has been duly adopted by the Corporation in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”) and has been approved by the requisite vote of the stockholders of the Corporation in accordance with the provisions of Section 228 of the DGCL. |
3. | This Certificate amends, restates and integrates the provisions of the Company’s Sixth Restated Certificate of Incorporation. |
4. | The text of the Sixth Restated Certificate of Incorporation of the Company is hereby amended and restated to read in its entirety as follows: |